UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
| | | | | |
| ☒ | QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended JuneSeptember 30, 2023
OR
| | | | | |
| ☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number 001-39990
Elicio Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | |
| Delaware | | | 11-3430072 |
(State or other jurisdiction of
incorporation or organization) | | | (I.R.S. Employer Identification No.) |
| | | |
| 451 D Street, 5th Floor Boston, Massachusetts | | | 02210 |
| (Address of Principal Executive Offices) | | | (Zip Code) |
(857) 209-0050
Registrant's telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | |
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common Stock, par value $0.01 | ELTX | The Nasdaq Global Select Market |
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-(§S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| | | | | | | | | | | |
| Large accelerated filer | ☐ | Accelerated filer | ☐ |
| Non-accelerated filer | ☒ | Smaller reporting company | ☒ |
| | Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
The number of shares of the issuer’s common stock outstanding as of August 10,November 7, 2023 was 8,388,457.8,407,106.
Forward-Looking Statements
This Quarterly Report on Form 10-Q, including the sections titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations”, contains forward-looking statements. We intend such forward-looking statements to be covered bywithin the safe harbor provisions for forward-looking statements contained in Section 27Ameaning of the Private Securities Litigation Reform Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any1995. All statements contained in this Quarterly Report on Form 10-Q that are notother than statements of historical facts may be deemed to befact, including statements concerning our business strategy and plans, future operating results and financial position, as well as our objectives and expectations for our future operations, are forward-looking statements.
In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would,” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are not limited to, statements about:
•our financial condition, including our ability to obtain the funding necessary to advance the development of ELI-002 and any other future product candidates, and our ability to continue as a going concern;
•the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results;
•our ability to utilize our platform to develop a pipeline of product candidates to address unmet needs in cancer and infectious disease;
•the timing, progress and results of clinical trials for ELI-002, and other product candidates we may develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the studies or trials will become available, and research and development programs;
•the timing, scope and likelihood of regulatory filings and approvals, including timing of INDs (as defined below) and U.S. Food and Drug Administration (“FDA”) approval of ELI-002 and any other future product candidates;
•the timing, scope or likelihood of foreign regulatory filings and approvals;
•our ability to develop and advance current product candidates and programs into, and successfully complete, clinical studies;
•our manufacturing, commercialization, and marketing capabilities and strategy;
•plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and sales strategy;
•the need to hire additional personnel and our ability to attract and retain such personnel;
•the size of the market opportunity for our product candidates, including estimates of the number of patients who suffer from the diseases we are targeting;
•expectations regarding the approval and use of our product candidates in combination with other drugs;
•our ability to secure drug product for combination studies;
•expectations regarding potential for accelerated approval or other expedited regulatory designation;
•our competitive position and the success of competing therapies that are or may become available;
•estimates of the number of patients that we will enroll in our clinical trials;
•the beneficial characteristicsanticipated research and the potential safety, efficacydevelopment activities and therapeutic effects of our product candidates;
•our ability to obtain and maintain regulatory approval of our product candidates and our expectations regarding particular lines of therapy;
•plans relating to the further development of our product candidates, including additional indications we may pursue;projected expenditures;
•existing regulations and regulatory developments in the United States, Europe and other jurisdictions;
•the effects of the ongoing COVID-19 pandemic,extent to which global economic and political developments, including the ongoing conflict between the Ukraine and Russia, and the recentconflicts in the Middle East, and potential future bank failures or other geopolitical events;events, will affect our business operations, clinical trials, or financial condition;
•our expectations regarding the impact of instability in the banking and financial services sector and other macroeconomic trends;
•our intellectual property position, including the scope of protection we are able to establish and maintain for intellectual property rights covering ELI-002, other product candidates we may develop, including the extensions of existing patent terms where available, the validity of intellectual property rights held by third parties, and our ability not to infringe, misappropriate or otherwise violate any third-party intellectual property rights;
•our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the manufacture of our product candidates for clinical trials;
•our relationships with patient advocacy groups, key opinion leaders, regulators, the research communityability to have manufactured sufficient supplies of drug product for clinical testing and payors;commercialization;
•our ability to obtain, and negotiate favorable terms of, any collaboration, licensing or other arrangements that may be necessary or desirable to develop, manufacture or commercialize our product candidates;
•the pricing and reimbursement of ELI-002, and other product candidates we may develop, if approved;
•the rate and degree of market acceptance and clinical utility of ELI-002 and other product candidates we may develop;
•our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
•our projected financial performance;
•the period over which we estimate our existing cash and cash equivalents will be sufficient to fund our planned operating expenses and capital expenditure requirements; and
•the impact of laws and regulations; and
•expectations regarding the period during which we will qualify as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and a smaller reporting company under the Exchange Act (as defined below).regulations.
We caution you that the foregoing list may not contain all of the forward-looking statements made in this Quarterly Report on Form 10-Q.
Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. We discuss these risks in greater detail in “Risk Factors”our Current Report on Form 8-K filed with the SEC on June 2, 2023 and elsewhere in this Quarterly Report on Form 10-Q. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, forward-looking statements represent our management’s beliefs and assumptions only as of the date of this Quarterly Report on Form 10-Q. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q. While we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into or review of all relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely on these statements.
This Quarterly Report on Form 10-Q also contains estimates, projections and other information concerning our industry, our business and the markets for certain drugs, including data regarding the estimated size of those markets, their projected growth rates and the incidence of certain medical conditions. Information that is based on estimates, forecasts, projections or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by third parties, industry, medical and general publications, government data and similar sources. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires.
EXPLANATORY NOTE
On June 1, 2023, the Delaware corporation formerly known as “Angion Biomedica Corp.”Elicio Operating Company, Inc. (“Former Elicio”), completed itsthe previously announced merger transaction in accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated as of January 17, 2023 (the “Merger Agreement”), by and among Angionthe Delaware corporation formerly known as “Angion Biomedica Corp.” (“Angion”), Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (“Merger Sub”), and Elicio Operating Company, Inc. (“Former Elicio”),Elicio, pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the “Merger”). Additionally, on June 1, 2023, Angion changed its name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.” (the “Company”).
Prior to the effective time of the Merger, on June 1, 2023, in connection with the transactions contemplated by the Merger Agreement, the Company effected a reverse stock split of the Company’s common stock, par value $0.01 per share (“Company common stock”), at a ratio of 10:1 (the “Reverse Stock Split”). At the effective time of the Merger, each outstanding share of Former Elicio capital stock (after giving effect to the automatic conversion of all shares of Former Elicio preferred stock into shares of Former Elicio common stock and excluding any shares held as treasury stock by Former Elicio or held or owned by Angion or any subsidiary of Angion or Former Elicio and any dissenting shares) was converted into the right to receive 0.0181 shares of Company common stock. The information in this Quarterly Report on Form 10-Q as of and for the periods prior to the effective date of the Merger gives effect to the Reverse Stock Split.
Since Former Elicio was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the condensed consolidated financial statements were prepared on a stand-alone basis for Former Elicio and did not include the combined entities’ activity or financial position. Subsequent to the Merger,
the condensed consolidated financial statements as of and for the three and sixnine months ended JuneSeptember 30, 2023 include the acquired business from June 2, 2023 through JuneSeptember 30, 2023, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of Former Elicio have been retroactively restated based on the exchange ratio of 0.0181.
In this Quarterly Report on Form 10-Q, unless the context indicates otherwise, the terms “Company,” “we,” “us,” and “our” refer to (i) Angion for periods prior to the effectiveness of the Merger and (ii) Elicio Therapeutics, Inc. (as
(as a combined company) for periods following the effectiveness of the Merger. Following the completion of the Merger, the business conducted by the Company became primarily the business conducted by Former Elicio.
This report contains references to trademarks belonging to other entities, which are the property of their respective holders. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Trademarks
This Quarterly Report on Form 10-Q includes trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this Quarterly Report on Form 10-Q are the property of their respective owners. We do not intend our use or display of other companies’ trade names or trademarks to imply a relationship with, or endorsement or sponsorship of us by, any other companies.
Part I FINANCIAL INFORMATION
Item 1. Financial Statements
ELICIO THERAPEUTICS, INC.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
(unaudited)
| | | June 30,
2023 | | December 31,
2022 | | September 30,
2023 | | December 31,
2022 |
| Assets | Assets | | | | Assets | | | |
| Current assets | Current assets | | Current assets | |
| Cash and cash equivalents | Cash and cash equivalents | $ | 21,682 | | | $ | 6,156 | | Cash and cash equivalents | $ | 14,841 | | | $ | 6,156 | |
| Restricted cash, current | Restricted cash, current | — | | | 1,641 | | Restricted cash, current | 1,671 | | | 1,641 | |
| Prepaid expenses and other current assets | Prepaid expenses and other current assets | 4,543 | | | 2,920 | | Prepaid expenses and other current assets | 3,419 | | | 2,920 | |
| Total current assets | Total current assets | 26,225 | | | 10,717 | | Total current assets | 19,931 | | | 10,717 | |
| Property and equipment, net | Property and equipment, net | 919 | | | 1,147 | | Property and equipment, net | 772 | | | 1,147 | |
| Operating lease, right-of-use assets | Operating lease, right-of-use assets | 6,952 | | | 7,350 | | Operating lease, right-of-use assets | 6,768 | | | 7,350 | |
| Restricted cash, noncurrent | Restricted cash, noncurrent | 681 | | | 618 | | Restricted cash, noncurrent | 683 | | | 617 | |
| Other long-term prepaid assets | Other long-term prepaid assets | 2,842 | | | 2,834 | | Other long-term prepaid assets | 2,833 | | | 2,833 | |
| Total assets | Total assets | $ | 37,619 | | | $ | 22,664 | | Total assets | $ | 30,987 | | | $ | 22,664 | |
| Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | | | | Liabilities, convertible preferred stock, and stockholders’ equity (deficit) | | | |
| Current liabilities | Current liabilities | | Current liabilities | |
| Accounts payable | Accounts payable | $ | 4,265 | | | $ | 2,805 | | Accounts payable | $ | 4,406 | | | $ | 2,805 | |
| Accrued expenses | Accrued expenses | 2,315 | | | 1,935 | | Accrued expenses | 4,416 | | | 1,935 | |
| | Deferred research obligation | Deferred research obligation | — | | | 1,436 | | Deferred research obligation | 1,664 | | | 1,436 | |
| Operating lease liability, current | Operating lease liability, current | 985 | | | 692 | | Operating lease liability, current | 938 | | | 692 | |
| Unvested option exercise liability, current | | Unvested option exercise liability, current | 36 | | | — | |
| Warrant liability | Warrant liability | 32 | | | — | | Warrant liability | 26 | | | — | |
| Total current liabilities | Total current liabilities | 7,597 | | | 6,868 | | Total current liabilities | 11,486 | | | 6,868 | |
| Operating lease liability, noncurrent | Operating lease liability, noncurrent | 6,419 | | | 6,789 | | Operating lease liability, noncurrent | 6,215 | | | 6,789 | |
| Unvested option exercise liability | 46 | | | 92 | | |
| Unvested option exercise liability, non current | | Unvested option exercise liability, non current | — | | | 92 | |
| Total liabilities | Total liabilities | 14,062 | | | 13,749 | | Total liabilities | 17,701 | | | 13,749 | |
| Commitments and contingencies - Note 10 | Commitments and contingencies - Note 10 | | | | Commitments and contingencies - Note 10 | |
| Convertible preferred stock: | Convertible preferred stock: | | Convertible preferred stock: | |
Series A convertible preferred stock, $0.06 par value: no shares and 132,387 shares authorized, issued and outstanding at June 30, 2023 and December 31, 2022, respectively | — | | | 7,495 | | |
Series B convertible preferred stock, $0.06 par value: no shares and 1,927,375 shares authorized, issued and outstanding at June 30, 2023 and December 31, 2022, respectively | — | | | 62,944 | | |
Series C convertible preferred stock, $0.06 par value: no shares and 4,888,798 shares authorized at June 30, 2023 and December 31, 2022, respectively; no shares and 2,938,158 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | — | | | 40,621 | | |
Series A convertible preferred stock, $0.06 par value: no shares and 132,387 shares authorized, issued and outstanding at September 30, 2023 and December 31, 2022, respectively | | Series A convertible preferred stock, $0.06 par value: no shares and 132,387 shares authorized, issued and outstanding at September 30, 2023 and December 31, 2022, respectively | — | | | 7,495 | |
Series B convertible preferred stock, $0.06 par value: no shares and 1,927,375 shares authorized, issued and outstanding at September 30, 2023 and December 31, 2022, respectively | | Series B convertible preferred stock, $0.06 par value: no shares and 1,927,375 shares authorized, issued and outstanding at September 30, 2023 and December 31, 2022, respectively | — | | | 62,944 | |
Series C convertible preferred stock, $0.06 par value: no shares and 4,888,798 shares authorized at September 30, 2023 and December 31, 2022, respectively; no shares and 2,938,158 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | | Series C convertible preferred stock, $0.06 par value: no shares and 4,888,798 shares authorized at September 30, 2023 and December 31, 2022, respectively; no shares and 2,938,158 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively | — | | | 40,621 | |
| Total convertible preferred stock | Total convertible preferred stock | — | | | 111,060 | | Total convertible preferred stock | — | | | 111,060 | |
| Stockholders' equity (deficit): | Stockholders' equity (deficit): | | | | Stockholders' equity (deficit): | | | |
| Common stock, $0.01 par value; 300,000,000 shares authorized at June 30, 2023 and December 31, 2022; 8,384,723 shares and 320,281 shares issued at June 30, 2023 and December 31, 2022, respectively; 8,370,268 and 320,281 outstanding as of June 30, 2023 and December 31, 2022, respectively | 84 | | | 3 | | |
| Treasury stock, at cost, 14,454 shares and no shares outstanding as of June 30, 2023 and December 31, 2022, respectively | (150) | | | — | | |
| Common stock, $0.01 par value; 300,000,000 shares authorized at September 30, 2023 and December 31, 2022; 8,384,723 shares and 320,281 shares issued at September 30, 2023 and December 31, 2022, respectively; 8,378,361 and 320,281 outstanding as of September 30, 2023 and December 31, 2022, respectively | | Common stock, $0.01 par value; 300,000,000 shares authorized at September 30, 2023 and December 31, 2022; 8,384,723 shares and 320,281 shares issued at September 30, 2023 and December 31, 2022, respectively; 8,378,361 and 320,281 outstanding as of September 30, 2023 and December 31, 2022, respectively | 84 | | | 3 | |
| Treasury stock, at cost, 14,455 shares and no shares outstanding as of September 30, 2023 and December 31, 2022, respectively | | Treasury stock, at cost, 14,455 shares and no shares outstanding as of September 30, 2023 and December 31, 2022, respectively | (150) | | | — | |
| Additional paid-in capital | Additional paid-in capital | 146,221 | | | 4,860 | | Additional paid-in capital | 146,631 | | | 4,860 | |
| Accumulated other comprehensive income | (2) | | | — | | |
| Accumulated other comprehensive income (loss) | | Accumulated other comprehensive income (loss) | (25) | | | — | |
| Accumulated deficit | Accumulated deficit | (122,596) | | | (107,008) | | Accumulated deficit | (133,254) | | | (107,008) | |
| Total stockholders' equity (deficit) | Total stockholders' equity (deficit) | 23,557 | | | (102,145) | | Total stockholders' equity (deficit) | 13,286 | | | (102,145) | |
| Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | $ | 37,619 | | | $ | 22,664 | | Total liabilities, convertible preferred stock, and stockholders' equity (deficit) | $ | 30,987 | | | $ | 22,664 | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
ELICIO THERAPEUTICS, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
(unaudited)
| | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | Three Months Ended
September 30, | | Nine Months Ended
September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 |
| | Operating expenses: | Operating expenses: | | | | | | | | Operating expenses: | | | | | | | |
| | Research and development | Research and development | 4,944 | | | 5,041 | | | 10,428 | | | 9,220 | | Research and development | $ | 7,264 | | | $ | 4,593 | | | $ | 17,692 | | | $ | 13,813 | |
| General and administrative | General and administrative | 2,833 | | | 1,191 | | | 5,154 | | | 2,782 | | General and administrative | 3,507 | | | 1,177 | | | 8,661 | | | 3,959 | |
| Total operating expenses | Total operating expenses | 7,777 | | | 6,232 | | | 15,582 | | | 12,002 | | Total operating expenses | 10,771 | | | 5,770 | | | 26,353 | | | 17,772 | |
| Loss from operations | Loss from operations | (7,777) | | | (6,232) | | | (15,582) | | | (12,002) | | Loss from operations | (10,771) | | | (5,770) | | | (26,353) | | | (17,772) | |
| Other income (expense) | Other income (expense) | | | | | | | | Other income (expense) | | | | | | | |
| Change in fair value of warrant liability | Change in fair value of warrant liability | (23) | | | — | | | (23) | | | — | | Change in fair value of warrant liability | 6 | | | — | | | (17) | | | — | |
| Change in fair value of embedded derivatives | Change in fair value of embedded derivatives | 321 | | | — | | | 429 | | | 74 | | Change in fair value of embedded derivatives | — | | | (360) | | | 429 | | | (286) | |
| | Gain on extinguishment of promissory notes payable | Gain on extinguishment of promissory notes payable | 604 | | | — | | | 604 | | | — | | Gain on extinguishment of promissory notes payable | — | | | — | | | 604 | | | — | |
| Foreign exchange transaction gain | (9) | | | — | | | (9) | | | — | | |
| Loss on sale of equipment | | Loss on sale of equipment | (105) | | | — | | | (105) | | | (4) | |
| Foreign exchange transaction loss | | Foreign exchange transaction loss | (33) | | | — | | | (45) | | | — | |
| Interest income | Interest income | 39 | | | — | | | 51 | | | 1 | | Interest income | 246 | | | 10 | | | 298 | | | 10 | |
| Interest expense | Interest expense | (714) | | | (1,067) | | | (1,056) | | | (2,432) | | Interest expense | (1) | | | (1,078) | | | (1,057) | | | (3,505) | |
| Total other income (expense) | Total other income (expense) | 218 | | | (1,067) | | | (4) | | | (2,357) | | Total other income (expense) | 113 | | | (1,428) | | | 107 | | | (3,785) | |
| Net loss | Net loss | (7,559) | | | (7,299) | | | (15,586) | | | (14,359) | | Net loss | (10,658) | | | (7,198) | | | (26,246) | | | (21,557) | |
| Other comprehensive loss: | Other comprehensive loss: | | Other comprehensive loss: | |
| Foreign currency translation adjustment | Foreign currency translation adjustment | (2) | | | — | | | (2) | | | — | | Foreign currency translation adjustment | (23) | | | — | | | (25) | | | — | |
| Comprehensive loss | Comprehensive loss | $ | (7,561) | | | $ | (7,299) | | | $ | (15,588) | | | $ | (14,359) | | Comprehensive loss | $ | (10,681) | | | $ | (7,198) | | | $ | (26,271) | | | $ | (21,557) | |
| Net loss per common share, basic and diluted | Net loss per common share, basic and diluted | $ | (2.44) | | | $ | (23.20) | | | $ | (9.06) | | | $ | (45.85) | | Net loss per common share, basic and diluted | $ | (1.27) | | | $ | (22.67) | | | $ | (3.19) | | | $ | (68.52) | |
| Weighted average common shares outstanding, basic and diluted | Weighted average common shares outstanding, basic and diluted | 3,100,957 | | | 314,572 | | | 1,720,202 | | | 313,148 | | Weighted average common shares outstanding, basic and diluted | 8,376,384 | | | 317,512 | | | 8,240,326 | | | 314,619 | |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
ELICIO THERAPEUTICS, INC.
Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit)
(in thousands, except share amounts)
(unaudited)
| | | Convertible Preferred Stock | | Common Stock | | Treasury Stock | | Additional Paid-in Capital | | Accumulated Other
Comprehensive Income | | Accumulated Deficit | | Total Stockholders' Equity (Deficit) | | | Convertible Preferred Stock | | Common Stock | | Treasury Stock | | Additional Paid-in Capital | | Accumulated Other Comprehensive Income (Loss) | | Accumulated Deficit | | Total Stockholders' Equity (Deficit) | |
| Shares | | Amount | | Shares | | Par Value | | Shares | | Amount | | | Shares | | Amount | | Shares | | Par Value | | Shares | | Amount | | |
Balance as of December 31, 2022 (1) | Balance as of December 31, 2022 (1) | 4,997,920 | | | $ | 111,060 | | | 320,281 | | | $ | 3 | | | — | | | $ | — | | | $ | 4,860 | | | $ | — | | | $ | (107,008) | | | $ | (102,145) | | | Balance as of December 31, 2022 (1) | 4,997,920 | | | $ | 111,060 | | | 320,281 | | | $ | 3 | | | — | | | $ | — | | | $ | 4,860 | | | $ | — | | | $ | (107,008) | | | $ | (102,145) | | |
| Exercise of stock options | Exercise of stock options | — | | | — | | | 4,699 | | | — | | | — | | | — | | | 40 | | | — | | | — | | | 40 | | | Exercise of stock options | — | | | — | | | 4,699 | | | — | | | — | | | — | | | 40 | | | — | | | — | | | 40 | | |
| Issuance of common stock upon net settlement of restricted stock units | Issuance of common stock upon net settlement of restricted stock units | — | | | — | | | 2,601 | | | — | | | — | | | — | | | 34 | | | — | | | — | | | 34 | | | Issuance of common stock upon net settlement of restricted stock units | — | | | — | | | 2,601 | | | — | | | — | | | — | | | 34 | | | — | | | — | | | 34 | | |
| Stock-based compensation | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 224 | | | — | | | — | | | 224 | | | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 224 | | | — | | | — | | | 224 | | |
| | Net loss | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (8,029) | | | (8,029) | | | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (8,029) | | | (8,029) | | |
| Balance as of March 31, 2023 | Balance as of March 31, 2023 | 4,997,920 | | | 111,060 | | | 327,581 | | | 3 | | | — | | | — | | | 5,158 | | | — | | | (115,037) | | | (109,876) | | | Balance as of March 31, 2023 | 4,997,920 | | | 111,060 | | | 327,581 | | | 3 | | | — | | | — | | | 5,158 | | | — | | | (115,037) | | | (109,876) | | |
| Exercise of stock options | Exercise of stock options | — | | | — | | | 4,460 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | Exercise of stock options | — | | | — | | | 4,460 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | |
| Issuance of common stock upon net settlement of restricted stock units | Issuance of common stock upon net settlement of restricted stock units | — | | | — | | | 903 | | | — | | | — | | | — | | | 11 | | | — | | | — | | | 11 | | | Issuance of common stock upon net settlement of restricted stock units | — | | | — | | | 903 | | | — | | | — | | | — | | | 11 | | | — | | | — | | | 11 | | |
| Conversion of preferred stock | Conversion of preferred stock | (4,997,920) | | | (111,060) | | | 4,997,920 | | | 50 | | | — | | | — | | | 111,010 | | | — | | | — | | | 111,060 | | | Conversion of preferred stock | (4,997,920) | | | (111,060) | | | 4,997,920 | | | 50 | | | — | | | — | | | 111,010 | | | — | | | — | | | 111,060 | | |
| Issuance of common stock to Angion stockholders as result of Merger and reset to par of $0.01, net of transaction cost of $2.4 million | Issuance of common stock to Angion stockholders as result of Merger and reset to par of $0.01, net of transaction cost of $2.4 million | — | | | — | | | 3,012,854 | | | 30 | | | — | | | — | | | 19,709 | | | — | | | — | | | 19,739 | | | Issuance of common stock to Angion stockholders as result of Merger and reset to par of $0.01, net of transaction cost of $2.4 million | — | | | — | | | 3,012,854 | | | 30 | | | — | | | — | | | 19,709 | | | — | | | — | | | 19,739 | | |
| Settlement of promissory notes in connection with Merger | Settlement of promissory notes in connection with Merger | — | | | — | | | — | | | — | | | — | | | — | | | 10,028 | | | — | | | — | | | 10,028 | | | Settlement of promissory notes in connection with Merger | — | | | — | | | — | | | — | | | — | | | — | | | 10,028 | | | — | | | — | | | 10,028 | | |
| Issuance of common stock upon accelerated vesting of restricted stock units due to Merger, net of treasury stock | Issuance of common stock upon accelerated vesting of restricted stock units due to Merger, net of treasury stock | — | | | — | | | 26,550 | | | 1 | | | — | | | — | | | 26 | | | — | | | — | | | 27 | | | Issuance of common stock upon accelerated vesting of restricted stock units due to Merger, net of treasury stock | — | | | — | | | 26,550 | | | 1 | | | — | | | — | | | 26 | | | — | | | — | | | 27 | | |
| Return of common stock to pay withholding taxes on restricted stock | Return of common stock to pay withholding taxes on restricted stock | — | | | — | | | — | | | — | | | (14,455) | | | (150) | | | — | | | — | | | — | | | (150) | | | Return of common stock to pay withholding taxes on restricted stock | — | | | — | | | — | | | — | | | (14,455) | | | (150) | | | — | | | — | | | — | | | (150) | | |
| Stock-based compensation | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 279 | | | — | | | — | | | 279 | | | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 279 | | | — | | | — | | | 279 | | |
| Foreign currency translation adjustment | Foreign currency translation adjustment | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (2) | | | — | | | (2) | | | Foreign currency translation adjustment | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (2) | | | — | | | (2) | | |
| Net loss | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (7,559) | | | (7,559) | | | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (7,559) | | | (7,559) | | |
| Balance as of June 30, 2023 | Balance as of June 30, 2023 | — | | | $ | — | | | 8,370,268 | | | $ | 84 | | | (14,455) | | | $ | (150) | | | $ | 146,221 | | | $ | (2) | | | $ | (122,596) | | | $ | 23,557 | | | Balance as of June 30, 2023 | — | | | — | | | 8,370,268 | | | 84 | | | (14,455) | | | (150) | | | 146,221 | | | (2) | | | (122,596) | | | 23,557 | | |
| Exercise of stock options | | Exercise of stock options | — | | | — | | | 7,190 | | | — | | | 60 | | | — | | | — | | | 60 | | |
| Issuance of common stock upon net settlement of restricted stock units | | Issuance of common stock upon net settlement of restricted stock units | — | | | — | | | 903 | | — | | | — | | | — | | | 11 | | | — | | | — | | | 11 | | |
| Stock-based compensation | | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 339 | | | — | | | — | | | 339 | | |
| Foreign currency translation adjustment | | Foreign currency translation adjustment | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (23) | | | — | | | (23) | | |
| Net loss | | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (10,658) | | | (10,658) | | |
| Balance as of September 30, 2023 | | Balance as of September 30, 2023 | — | | | $ | — | | | 8,378,361 | | | $ | 84 | | | (14,455) | | | $ | (150) | | | $ | 146,631 | | | $ | (25) | | | $ | (133,254) | | | $ | 13,286 | | |
|
(1) Retroactively restated for the reverse recapitalization as described in Note 3.
| | | Convertible Preferred Stock | | Common Stock | | Treasury Stock | | Additional Paid-in Capital | | Accumulated Other
Comprehensive Loss | | Accumulated Deficit | | Total Stockholders' Equity (Deficit) | | | Convertible Preferred Stock | | Common Stock | | Treasury Stock | | Additional Paid-in Capital | | Accumulated Other
Comprehensive Loss | | Accumulated Deficit | | Total Stockholders' Equity (Deficit) | |
| Shares | | Amount | | Shares | | Par Value | | Shares | | Amount | | | Shares | | Amount | | Shares | | Par Value | | Shares | | Amount | | |
Balance as of December 31, 2021 (1) | Balance as of December 31, 2021 (1) | 1,408,100 | | | $ | 70,439 | | | 310,200 | | | $ | 3 | | | — | | | $ | — | | | $ | 4,261 | | | $ | — | | | $ | (78,801) | | | $ | (74,537) | | | Balance as of December 31, 2021 (1) | 1,408,100 | | | $ | 70,439 | | | 310,200 | | | $ | 3 | | | — | | | $ | — | | | $ | 4,261 | | | $ | — | | | $ | (78,801) | | | $ | (74,537) | | |
| | Exercise of stock options | Exercise of stock options | — | | | — | | | 71 | | | — | | | — | | | — | | | 1 | | | — | | | — | | | 1 | | | Exercise of stock options | — | | | — | | | 71 | | | — | | | — | | | — | | | 1 | | | — | | | — | | | 1 | | |
| Vesting of restricted common stock | Vesting of restricted common stock | — | | | — | | | 2,775 | | | — | | | — | | | — | | | 3 | | | — | | | — | | | 3 | | | Vesting of restricted common stock | — | | | — | | | 2,775 | | | — | | | — | | | — | | | 3 | | | — | | | — | | | 3 | | |
| Stock-based compensation | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 157 | | | — | | | — | | | 157 | | | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 157 | | | — | | | — | | | 157 | | |
| | Net loss | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (7,060) | | | (7,060) | | | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (7,060) | | | (7,060) | | |
| Balance as of March 31, 2022 | Balance as of March 31, 2022 | 1,408,100 | | | 70,439 | | | 313,046 | | | 3 | | | — | | | — | | | 4,422 | | | — | | | (85,861) | | | (81,436) | | | Balance as of March 31, 2022 | 1,408,100 | | | 70,439 | | | 313,046 | | | 3 | | | — | | | — | | | 4,422 | | | — | | | (85,861) | | | (81,436) | | |
| Vesting of restricted common stock | Vesting of restricted common stock | — | | | — | | | 2,775 | | | — | | | — | | | — | | | 3 | | | — | | | — | | | 3 | | | Vesting of restricted common stock | — | | | — | | | 2,775 | | | — | | | — | | | — | | | 3 | | | — | | | — | | | 3 | | |
| Exercise of stock options | Exercise of stock options | — | | | — | | | 181 | | | — | | | — | | | — | | | 3 | | | — | | | — | | | 3 | | | Exercise of stock options | — | | | — | | | 181 | | | — | | | — | | | — | | | 3 | | | — | | | — | | | 3 | | |
| Issuance of Series C convertible preferred stock, net of issuance costs of approximately $0.3 million | Issuance of Series C convertible preferred stock, net of issuance costs of approximately $0.3 million | 103,637 | | | 1,169 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | Issuance of Series C convertible preferred stock, net of issuance costs of approximately $0.3 million | 103,637 | | | 1,169 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | |
| Stock-based compensation | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 113 | | | — | | | — | | | 113 | | | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 113 | | | — | | | — | | | 113 | | |
| Net loss | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (7,299) | | | (7,299) | | | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (7,299) | | | (7,299) | | |
| Balance as of June 30, 2022 | Balance as of June 30, 2022 | 1,511,737 | | | $ | 71,608 | | | 316,002 | | | $ | 3 | | | — | | | $ | — | | | $ | 4,541 | | | $ | — | | | $ | (93,160) | | | $ | (88,616) | | | Balance as of June 30, 2022 | 1,511,737 | | | 71,608 | | | 316,002 | | | 3 | | | — | | | — | | | 4,541 | | | — | | | (93,160) | | | (88,616) | | |
| Issuance of Series C convertible preferred stock, net of issuance costs of approximately $0.7 million | | Issuance of Series C convertible preferred stock, net of issuance costs of approximately $0.7 million | 668,942 | | | 8,840 | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | |
| Exercise of stock options | | Exercise of stock options | — | | | — | | | 341 | | | — | | | — | | | — | | | 4 | | | — | | | — | | | 4 | | |
| Vesting of restricted common stock | | Vesting of restricted common stock | — | | | — | | | 2,775 | | | — | | | — | | | — | | | 3 | | | — | | | — | | | 3 | | |
| Stock-based compensation | | Stock-based compensation | — | | | — | | | — | | | — | | | — | | | — | | | 110 | | | — | | | — | | | 110 | | |
| Net loss | | Net loss | — | | | — | | | — | | | — | | | — | | | — | | | — | | | — | | | (7,198) | | | (7,198) | | |
| Balance as of September 30, 2022 | | Balance as of September 30, 2022 | 2,180,679 | | | $ | 80,448 | | | 319,118 | | | $ | 3 | | | — | | | $ | — | | | $ | 4,658 | | | $ | — | | | $ | (100,358) | | | $ | (95,697) | | |
|
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
(1) Retroactively restated for the reverse recapitalization as described in Note 3.
ELICIO THERAPEUTICS, INC.
Condensed Consolidated Statements of Cash Flows
(in thousands)
(unaudited)
| | | Six Months Ended
June 30, | | Nine Months Ended
September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
| Cash flows from operating activities: | Cash flows from operating activities: | | | | Cash flows from operating activities: | | | |
| Net loss | Net loss | $ | (15,586) | | | $ | (14,359) | | Net loss | $ | (26,246) | | | $ | (21,557) | |
| Adjustments to reconcile net loss to net cash used in operating activities: | Adjustments to reconcile net loss to net cash used in operating activities: | | Adjustments to reconcile net loss to net cash used in operating activities: | |
| Depreciation | Depreciation | 214 | | | 186 | | Depreciation | 302 | | | 290 | |
| Amortization of right-of-use assets, operating leases | Amortization of right-of-use assets, operating leases | 397 | | | 283 | | Amortization of right-of-use assets, operating leases | 582 | | | 473 | |
| Non-cash interest expense | Non-cash interest expense | 1,061 | | | 2,431 | | Non-cash interest expense | 1,061 | | | 3,509 | |
| Change in fair value of embedded derivative | Change in fair value of embedded derivative | (429) | | | (74) | | Change in fair value of embedded derivative | (429) | | | 286 | |
| Change in fair value of warrant liability | Change in fair value of warrant liability | 23 | | | — | | Change in fair value of warrant liability | 17 | | | — | |
| Stock-based compensation | Stock-based compensation | 503 | | | 270 | | Stock-based compensation | 842 | | | 380 | |
| Gain on extinguishment of promissory note payable | Gain on extinguishment of promissory note payable | (604) | | | — | | Gain on extinguishment of promissory note payable | (604) | | | — | |
| Loss on disposal of property and equipment, net | Loss on disposal of property and equipment, net | 1 | | | 4 | | Loss on disposal of property and equipment, net | 105 | | | 4 | |
| Changes in operating assets and liabilities: | Changes in operating assets and liabilities: | | Changes in operating assets and liabilities: | |
| Prepaid expenses and other current assets | Prepaid expenses and other current assets | (1,083) | | | (16) | | Prepaid expenses and other current assets | (41) | | | (1,513) | |
| Other long-term prepaid assets | Other long-term prepaid assets | (8) | | | 114 | | Other long-term prepaid assets | — | | | 114 | |
| Accounts payable | Accounts payable | (79) | | | 1,759 | | Accounts payable | 63 | | | 1,407 | |
| Accrued expenses | (251) | | | 109 | | |
| Accrued expenses and other current liabilities | | Accrued expenses and other current liabilities | 1,910 | | | (70) | |
| Deferred research obligation | Deferred research obligation | (1,436) | | | — | | Deferred research obligation | 228 | | | 2,152 | |
| Operating lease liabilities | Operating lease liabilities | (337) | | | (224) | | Operating lease liabilities | (588) | | | (378) | |
| | Net cash used in operating activities | Net cash used in operating activities | (17,614) | | | (9,517) | | Net cash used in operating activities | (22,798) | | | (14,903) | |
| Cash flows from investing activities: | Cash flows from investing activities: | | | | Cash flows from investing activities: | | | |
| Purchases of property and equipment | Purchases of property and equipment | (21) | | | (559) | | Purchases of property and equipment | (66) | | | (559) | |
| Proceeds from sale of property and equipment | Proceeds from sale of property and equipment | 34 | | | — | | Proceeds from sale of property and equipment | 34 | | | — | |
| Net cash provided by (used in) investing activities | 13 | | | (559) | | |
| Net cash used in investing activities | | Net cash used in investing activities | (32) | | | (559) | |
| Cash flows from financing activities: | Cash flows from financing activities: | | | | Cash flows from financing activities: | | | |
| Cash acquired in connection with the reverse merger | Cash acquired in connection with the reverse merger | 24,001 | | | — | | Cash acquired in connection with the reverse merger | 24,000 | | | — | |
| Merger transaction costs | Merger transaction costs | (2,366) | | | Merger transaction costs | (2,366) | | | — | |
| Proceeds from issuance of promissory notes payable | Proceeds from issuance of promissory notes payable | 10,000 | | | — | | Proceeds from issuance of promissory notes payable | 10,000 | | | — | |
| Proceeds from issuance of Series C-1 convertible preferred stock, net of issuance costs | Proceeds from issuance of Series C-1 convertible preferred stock, net of issuance costs | — | | | 1,169 | | Proceeds from issuance of Series C-1 convertible preferred stock, net of issuance costs | — | | | 10,009 | |
| Payment for purchase of treasury stock | Payment for purchase of treasury stock | (150) | | | — | | Payment for purchase of treasury stock | (150) | | | — | |
| Exercise of stock options | Exercise of stock options | 67 | | | 78 | | Exercise of stock options | 127 | | | 17 | |
| Net cash provided by financing activities | Net cash provided by financing activities | 31,552 | | | 1,247 | | Net cash provided by financing activities | 31,611 | | | 10,026 | |
| Effect of foreign currency on cash | Effect of foreign currency on cash | (2) | | | — | | Effect of foreign currency on cash | — | | | — | |
| Net increase (decrease) in cash and cash equivalents | 13,949 | | | (8,829) | | |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | | Net increase (decrease) in cash, cash equivalents, and restricted cash | 8,781 | | | (5,436) | |
| Cash, cash equivalents and restricted cash at beginning of period | Cash, cash equivalents and restricted cash at beginning of period | 8,414 | | | 10,045 | | Cash, cash equivalents and restricted cash at beginning of period | 8,414 | | | 10,045 | |
| Cash, cash equivalents and restricted cash at the end of the period | Cash, cash equivalents and restricted cash at the end of the period | $ | 22,363 | | | $ | 1,216 | | Cash, cash equivalents and restricted cash at the end of the period | $ | 17,195 | | | $ | 4,609 | |
| | Components of cash, cash equivalents and restricted cash: | Components of cash, cash equivalents and restricted cash: | | Components of cash, cash equivalents and restricted cash: | |
| Cash and cash equivalents | Cash and cash equivalents | $ | 21,682 | | | $ | 598 | | Cash and cash equivalents | $ | 14,841 | | | $ | 1,839 | |
| Restricted cash | Restricted cash | 681 | | | 618 | | Restricted cash | 2,354 | | | 2,770 | |
| Total cash, cash equivalents and restricted cash | Total cash, cash equivalents and restricted cash | $ | 22,363 | | | $ | 1,216 | | Total cash, cash equivalents and restricted cash | $ | 17,195 | | | $ | 4,609 | |
| | Supplemental disclosure of noncash investing and financing activities: | Supplemental disclosure of noncash investing and financing activities: | | Supplemental disclosure of noncash investing and financing activities: | |
| Loss on disposal of property and equipment | Loss on disposal of property and equipment | $ | 1 | | | $ | 4 | | Loss on disposal of property and equipment | $ | 139 | | | $ | 4 | |
| Accretion of promissory note discount from embedded derivative | Accretion of promissory note discount from embedded derivative | $ | 130 | | | $ | — | | Accretion of promissory note discount from embedded derivative | $ | 130 | | | $ | — | |
| Accretion of promissory note to face value | Accretion of promissory note to face value | $ | 897 | | | $ | — | | Accretion of promissory note to face value | $ | 897 | | | $ | — | |
| Settlement of promissory notes payable | Settlement of promissory notes payable | $ | 10,028 | | | $ | — | | Settlement of promissory notes payable | $ | 10,028 | | | $ | — | |
| Interest expense from convertible notes payable | Interest expense from convertible notes payable | $ | 34 | | | $ | — | | Interest expense from convertible notes payable | $ | 34 | | | $ | — | |
| Accretion of convertible notes discount from embedded derivative | Accretion of convertible notes discount from embedded derivative | $ | — | | | $ | 1,639 | | Accretion of convertible notes discount from embedded derivative | $ | — | | | $ | 1,639 | |
| Accretion of convertible notes discount from issuance costs | Accretion of convertible notes discount from issuance costs | $ | — | | | $ | 219 | | Accretion of convertible notes discount from issuance costs | $ | — | | | $ | 219 | |
| Interest expense from convertible notes payable | Interest expense from convertible notes payable | $ | — | | | $ | 574 | | Interest expense from convertible notes payable | $ | — | | | $ | 574 | |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements
Note 1—Description of the Business and Financial Condition
Elicio Therapeutics, Inc. (“Elicio” or the “Company”) was incorporated in Delaware as Vedantra Pharmaceuticals Inc., in August 2011. Elicio is a clinical-stage biotechnology company pioneeringdeveloping a pipeline of novel immunotherapies for the developmenttreatment of therapeutic cancer vaccines for patients with limited treatment options and poor outcomes.cancer. In December 2018, Elicio formed a wholly-owned subsidiary, Elicio Securities Corporation (“ESC”), a Massachusetts corporation. ESC is an investment company. Elicio and ESC are collectively referred to as “Elicio” throughout these unaudited consolidated financial statements.
Reverse Merger Transaction
On January 17, 2023, the Company entered into a definitive merger agreement (the “Merger Agreement”) with Angion Biomedica Corp. (“Angion”), a clinical development corporation. In accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, by and among Angion, Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (“Merger Sub”), Angion Pty Ltd., a wholly owned subsidiary of Angion, and Elicio Operating Company, Inc. (“Former Elicio”), pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the “Merger”).
On June 1, 2023, the Company completed the Merger in accordance with the terms and conditions of the Merger Agreement and Angion changed its name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.” Immediately following the consummation of the Merger, there were approximately 9.7 million shares of the Company’s common stock outstanding on a fully-diluted basis, with Former Elicio equity holders collectively owning approximately 65.2% of the Company and Angion equity holders collectively owning approximately 34.8% of the Company, in each case on a fully diluted basis.
The Merger was accounted for as a reverse recapitalization, with Former Elicio being treated as the acquirer for accounting purposes. See discussions of the transactions in connection with the Merger at Note 3 - Merger and Related Transactions.
Liquidity and Going Concern
The Company has experienced net losses and negative cash flows from operating activities since inception. As of JuneSeptember 30, 2023, the Company had an accumulated deficit of $122.6$133.3 million. The Company expects that its operating losses and operating cash flows will continue for the foreseeable future as the Company continues to develop its product candidates.
As of JuneSeptember 30, 2023, the Company had $21.7$14.8 million in cash and cash equivalents. The Company’s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the condensed consolidated financial statements, raise substantial doubt about the Company’s ability to continue as a going concern. The Company expects to incur substantial expenditures in the foreseeable future for the development of its product candidates and will require additional financing to continue this development. The Company plans to address this condition through the sale of Company common stock in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all.If the Company is unable to obtain additional capital when and as needed to continue as a going concern, it might have to further reduce or scale back its operations and/or liquidate its assets, and the values it receives for its assets in liquidation or dissolution could be significantly lower than the values reflected in its financial statements.
The accompanying unaudited condensed consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
Note 2—Summary of Significant Accounting Policies
Basis of Presentation
The Company's unaudited condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting, consistent in all material respects with those applied in the Company’s audited financial statements and accompanying notes for the year ended December 31, 2022 and 2021 included in the Company’s proxy statement/prospectus/information statement on Form S-4 filed April 26, 2023, as amended (the “Form S-4”). Any reference in these notes to
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
applicable guidance is meant to refer to the authoritative accounting principles generally accepted in the United States as found in the Accounting Standard Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). This report should be read in conjunction with the audited consolidated financial statements in the Form S-4.
The condensed consolidated financial statements include the accounts of the Company, its wholly owned subsidiary, Angion Pty Ltd. (“Angion Pty”), which was established on August 22, 2019, and its wholly-owned subsidiary, ESC, which was established in Massachusetts in December 2018. The Company established Angion Pty, Ltd., an Australian subsidiary, for the purpose of qualifying for research credits for studies conducted in Australia and ESC is an investment company. All significant intercompany balances and transactions have been eliminated in consolidation.
The Company’s significant accounting policies are described in Note 2 to its consolidated financial statements for the year ended December 31, 2022, included in its Form S-4. There have been no material changes to the Company’s significant accounting policies during the sixnine months ended JuneSeptember 30, 2023.
Since Former Elicio was determined to be the accounting acquirer in connection with the Merger, for periods prior to the Merger, the condensed consolidated financial statements were prepared on a stand-alone basis for Former Elicio and did not include the combined entities activity or financial position. Subsequent to the Merger, the condensed consolidated financial statements as of and for the three and sixnine months ended JuneSeptember 30, 2023 include the acquired business from June 2, 2023 through JuneSeptember 30, 2023, and assets and liabilities at their acquisition date fair value. Historical share and per share figures of the Former Elicio have been retroactively restated based on the exchange ratio of 0.0181.
Segments
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating decision-maker (“CODM”) in making decisions regarding resource allocation and assessing performance. The Company views its operations and manages its business as one operating segment. The Company has determined that the chief executive officer is the CODM.
Use of Estimates
The Company’s management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the condensed consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could materially differ from those estimates. Significant estimates reflected in these condensed consolidated financial statements include but are not limited to, the accrual of research and development expenses, the valuation of stock-based awards, the operating right of use assets and operating lease liability, and going concern.
Foreign Currency Translation and Transactions
The United States Dollar (“USD”) is the functional currency for the Company’s operations outside the United States. Accordingly, nonmonetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into USD at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity’s
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
functional currency are included in other income (expense) in the accompanying condensed consolidated statements of operations and comprehensive loss.
Concentrations of Credit Risk and Off-Balance Sheet Risk
Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash, cash equivalents, and restricted cash. At times, cash balances deposited at major financial banking institutions exceed the federally insured limit. The Company regularly monitors the financial condition of the institutions in which it has depository accounts and believes the risk of loss is minimal. The Company has not experienced any losses in such accounts.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
Cash and Cash Equivalents
Cash and cash equivalents are comprised of deposits at major financial banking institutions and highly liquid investments with an original maturity of three months or less at the date of purchase. As of JuneSeptember 30, 2023 and December 31, 2022, the Company’s cash equivalents were held in institutions in the United States and include deposits in a money market fund which were unrestricted as to withdrawal or use.
Restricted Cash
Restricted cash consists of cash securing a collateral letter of credit issued in connection with the Company’s facility operating lease and a research grant. See notes 6 and 10 for further discussion.
Fair Value Measurement
The Company follows the guidance prescribed by ASC Topic 820, Fair Value Measurements, which establishes a framework for measuring fair value, and expands disclosures about fair value measurements. The standard provides a consistent definition of fair value that focuses on an exit price which is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The standard establishes a three-level hierarchy for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date.
Level 1: Observable inputs such as unadjusted quoted prices in active markets for identical assets or liabilities at measurement.
Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.
Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized in Level 3. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.
The carrying amounts of financial instruments reflected in the condensed consolidated balance sheets for cash and cash equivalents, current and non-current restricted cash, accounts payable, and accrued expenses approximate their respective fair values because of the short-term maturity of those financial instruments.
Property and Equipment
Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful life of the asset. Upon sale or retirement, the cost and accumulated depreciation are eliminated
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
from their respective accounts, and the resulting gain or loss is recorded in the consolidated statement of operations and comprehensive loss. Repair and maintenance expenditures are charged to expense as incurred.
| | | | | | | | | | | | | | |
| Asset Class | | | Estimated Useful Lives |
| Equipment | | | 5 years |
| Furniture and fixtures | | | 3 years |
| Leasehold improvements | | | Term of the lease |
Impairment of Long-Lived Assets
Periodically, the Company evaluates its long-lived assets, which consist primarily of property and equipment, and right of use asset for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. Recoverability of assets to be held and used is measured by a
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
comparison of the carrying amount of an asset to the future undiscounted net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value of the asset. During the three and sixnine months ended JuneSeptember 30, 2023 and 2022, no impairments have occurred.
Derivative Financial Instruments
The convertible and promissory notes include embedded derivatives requiring bifurcation in accordance with ASC 815, Derivatives and Hedging. The valuation of the instruments are determined using widely accepted valuation techniques including the probability weighted expected return model. The fair value was determined using a model with the assumptions for equity value proceeds, probability of occurrence of various liquidation scenarios, timeline to liquidity and risk-free interest rate. The fair value of the derivative instruments are measured at each reporting period with changes in fair value reported in earnings (loss).
Convertible Preferred Stock
Former Elicio had classified convertible preferred stock, par value $0.06 per share, (the “Preferred Stock”) as temporary equity in the accompanying consolidated balance sheets due to certain changes in control events that are outside of the Former Elicio’s control, including sale or transfer of control of Former Elicio, as holders of the Preferred Stock could cause redemption of the shares in these situations. Former Elicio did not accrete the carrying values of the Preferred Stock to the redemption values since a liquidation event was not considered probable as of December 31, 2022. Subsequent adjustments of the carrying values to the ultimate redemption values would be made only if it becomes probable that such a liquidation event will occur. During thisthe prior reporting period an immaterial error was discovered in Former Elicio's 2022 audited financial statements whereas the amount of Series A and Series B Preferred Stock did not include 41,887 and 609,755 shares, respectively, that were deemed to be issued due to the antidilutive protection triggered by the Series C shares issued in October 2022 at a price below $1.00. As a result of the Merger, all Former Elicio preferred stock were converted into Company common stock on June 1, 2023. See Note 7.
Income Taxes
The Company provides for income taxes in accordance with ASC Topic 740, Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws in effect in the years in which the differences are expected to reverse. A valuation allowance is provided if, based upon the weighted available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.
The Company provides reserves for potential payments of tax to various tax authorities related to uncertain tax positions when the Company management determines that it is probable that a loss will be incurred related to these matters and the amount of the loss is reasonably determinable. The Company has not identified any significant uncertain tax positions as of JuneSeptember 30, 2023.
Research and Development
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
Research and development costs are charged to expense as incurred and consist of expenses incurred in performing research and development activities, including salaries and benefits, materials and supplies, preclinical expenses, stock-based compensation expense, depreciation of equipment, contract services, and other outside expenses. The Company accrues for costs incurred by external service providers, based on estimates of services performed and costs. These estimates include the level of services performed by the third parties, and other indicators of the services completed. Based on the timing of payments to service providers, the Company may also record prepaid expenses for those service providers that will be recognized as expenses in future periods as the related services are rendered. Research and development costs may be offset by research and development refundable tax rebates received by the Company’s wholly-owned Australian subsidiary.
Leases
ASU No. 2016-02, Leases (“ASC 842”) establishes a right-of-use model (“ROU”) that requires a lessee to recognize a ROU asset and corresponding lease liability on the balance sheet for all leases with a term longer than 12 months. Leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the statement of operations as well as the reduction of the ROU asset.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on specific facts and circumstances, the existence of an identified asset(s), if any, and the Company’s control over the use of the identified asset(s), if applicable. Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of future lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company will utilize the incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment.
The Company has elected to combine lease and non-lease components as a single component. Operating leases are recognized on the condensed consolidated balance sheet as ROU lease assets, current lease liabilities and non-current lease liabilities. Fixed rents are included in the calculation of the lease balances, while variable costs paid for certain operating and pass-through costs are excluded. Lease expense is recognized over the expected term on a straight-line basis.
Research Grant
The Company recognizes the amount of grant income based on the activity in allowable expenses covered under the grant and has elected to recognize the funds earned as an offset to the related research expenses recorded in operations. Advances from the grant that have yet to be recognized are recorded as restricted cash if the grant requires the funds to be isolated from general cash and cash equivalents. The Company records a liability for any research activity that is required under the grant but has not yet been performed. The liability is recorded as deferred research obligation on the condensed consolidated balance sheets.
Stock-based Compensation
The Company issues stock-based awards to employees and non-employees, generally in the form of stock options. The Company accounts for stock-based awards in accordance with ASC 718, Compensation—Stock Compensation, which requires all stock-based payments, to be recognized in the condensed consolidated statements of operations based on their fair values. The expense is recognized on a straight line basis over the requisite service period, which is generally the vesting period. The Company has elected to account for option forfeitures as they occur.
The Company uses the Black-Scholes option-pricing model (“Black-Scholes”) to determine the weighted-average fair value of options granted, which uses as inputs the fair value of the Common Stock,Company common stock, assumptions the Company makes for the volatility of its Common Stock,Company common stock, the expected term of its stock options, the risk-free interest rate for a period that approximates the expected term of its stock options and its expected dividend yield.
Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period.
Prior to the merger,Merger, there was no public market for Former Elicio’s Common Stock.common stock. The estimated fair value of the Common StockCompany common stock underlying Former Elicio’s stock-based awards was determined by Former Elicio’s Boardboard of Directorsdirectors as of the grant date of each option grant. To determine the fair value of Former Elicio’s common
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
stock underlying option grants, theFormer Elicio’s board of directors considered, among other things, input from management and valuations of Former Elicio's common stock prepared by third-party valuation firms performed in accordance with the guidance outlined in the American Institute of Certified Public Accountants' Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation. Following the Merger, the fair value of Company common stock is based on the closing stock price on the date of grant as reported on the Nasdaq Global Select Market.
Net Loss Per Share
Basic net loss per share of Company common stock is computed by dividing net loss attributable to Company common stockholders by the weighted average number of shares of Company common stock outstanding for the period. Diluted net loss per share excludes the potential impact of Company common stock options, warrants and unvested shares of restricted stock because their effect would be anti-dilutive due to the Company's net loss. Since the Company had net losses for the three and sixnine months ended JuneSeptember 30, 2023 and 2022, basic and diluted net loss per common share are the same.
Recently Adopted Accounting Pronouncements
In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326) Measurement of Credit Losses on Financial Instruments (ASU No. 2016-13), which requires an entity to utilize a new impairment model known as the current expected credit loss (“CECL”) model to estimate its lifetime “expected credit loss” and record an allowance that, when deducted from the amortized cost basis of the financial assets and
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
certain other instruments, including but not limited to, available-for-sale debt securities. Credit losses relating to available-for-sale debt securities will be recorded through an allowance for credit losses rather than as a direct write-down to the security. The Company adopted ASU No. 2016-13 on January 1, 2023 and the adoption of the standard had no material impact on its condensed consolidated financial statements.
Note 3—Merger and Related Transactions
As described in Note1,Note 1, Former Elicio merged with a wholly owned subsidiary of Angion on June 1, 2023. The Merger was accounted for as a reverse recapitalization under U.S. GAAP. Former Elicio was considered the accounting acquirer for financial reporting purposes. This determination was based on the facts that, immediately following the Merger: (i) Former Elicio stockholders own a substantial majority of the voting rights; (ii) Former Elicio designated a majority (six of nine) of the initial members of the Company’s board of directors of the combined company; (iii) Former Elicio’s executive management team became the management team of the combined company; and (iv) the Company was named Elicio Therapeutics, Inc. and is headquartered in Boston, Massachusetts. Accordingly, for accounting purposes, the Merger was treated as the equivalent of Former Elicio issuing stock to acquire the net assets of Angion. As a result of the Merger, the net assets of Angion were recorded at their acquisition-date fair value, which approximated book value due to the short-term nature of the instruments, in the financial statements of Former Elicio and the reported operating results prior to the Merger were those of Former Elicio. Historical common share amounts of Former Elicio have been retroactively restated based on the exchange ratio of 0.0181 (the “Exchange Ratio”). It was concluded that any in-process research and development assets that remained as of the Merger would be de minimis when compared to the cash and investments obtained through the Merger.
Prior to the effective time of the Merger, on June 1, 2023, in connection with the transactions contemplated by the Merger Agreement, the Company effected a reverse stock split of Angion’s common stock, par value $0.01 per share (“Angion common stock”), at a ratio of 10:1 (the “Reverse Stock Split”). At the effective time of the Merger, each outstanding share of Former Elicio capital stock (after giving effect to the automatic conversion of all shares of Former Elicio preferred stock into shares of Former Elicio common stock and excluding any shares held as treasury stock by Former Elicio or held or owned by Angion or any subsidiary of Angion or Former Elicio and any dissenting shares) was converted into the right to receive 0.0181 shares of Angion common stock, which resulted in the issuance by Angion of an aggregate of 5,375,751 shares of Angion common stock to the stockholders of Former Elicio (the “Exchange Shares”), and a total of 8,387,025 shares of the Company common stock being issued and outstanding immediately following the effective time of the Merger. In addition, Angion assumed the Elicio 2022 Equity Incentive Plan and the Elicio 2012 Equity Incentive Plan (the “Elicio Plans”) and each outstanding and unexercised option to purchase Former Elicio common stock and each outstanding and unexercised warrant to
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
purchase Former Elicio capital stock were adjusted with such stock options and warrants henceforth representing the right to purchase a number of shares of the Company’s common stock equal to the Exchange Ratio multiplied by the number of shares of Former Elicio common stock previously represented by such options, and warrants.warrants at an exercise price equal to the exercise price of Former Elicio capital stock divided by the Exchange Ratio.
In connection with execution of the Merger Agreement, Angion made a bridge loan to Former Elicio pursuant to a note purchase agreement and promissory notes up to an aggregate principal amount of $12.5 million, issued with a 20% original issue discount, with an initial closing held substantially concurrently with the execution of the Merger Agreement for a principal amount of $6.25 million on account of a $5.0 million loan and an additional closing for a principal amount of $6.25 million on account of a $5.0 million loan upon delivery by Former Elicio to Angion of Former Elicio’s audited financial statements for the year ended December 31, 2022.
As part of the recapitalization, the Company obtained the assets and liabilities listed below (in thousands):
| | | | | | | | |
| Cash and cash equivalents | $ | 24,000 | |
| Other current assets | 539 | |
| Promissory Notesnotes | 10,028 | |
| Accrued liabilities | (2,438) | |
| Net assets acquired | $ | 32,129 | |
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
Per the terms of the Merger Agreement, upon completion of the Merger, all obligations owed by Former Elicio related to the bridge loanpromissory notes were automatically forgiven and the amount advanced by Angion, along with any accrued and unpaid interested,interest, was credited towards the net cash balance used to calculate the assets and liabilities listed above. Upon settlement of the bridge loan,promissory notes, the Company recognized a gain of $0.6 million related to the fair valueextinguishment of the embedded derivatives associated with the bridge loan.promissory notes.
The Company recognized the net assets acquired, excluding the promissory notes and transaction costs of $2.9 million, as a reduction to additional paid-in capital in the condensed consolidated statements of convertible preferred stock and stockholders’ equity (deficit) for the three and sixnine months ended JuneSeptember 30, 2023.
Note 4—Fair Value Measurements
The following tables present the Company's financial assets and liabilities measured at fair value on a recurring basis and their assigned levels within the fair value hierarchy (in thousands):
| | | June 30, 2023 | | September 30, 2023 |
| | Level 1 | | Level 2 | | Level 3 | | Total | | Level 1 | | Level 2 | | Level 3 | | Total |
Money market funds(1) | Money market funds(1) | $ | 18,634 | | | $ | — | | | $ | — | | | $ | 18,634 | | Money market funds(1) | $ | 16,302 | | | $ | — | | | $ | — | | | $ | 16,302 | |
| | Total assets | Total assets | $ | 18,634 | | | $ | — | | | $ | — | | | $ | 18,634 | | Total assets | $ | 16,302 | | | $ | — | | | $ | — | | | $ | 16,302 | |
| Warrant liabilities | Warrant liabilities | $ | — | | | $ | — | | | $ | 32 | | | $ | 32 | | Warrant liabilities | $ | — | | | $ | — | | | $ | 26 | | | $ | 26 | |
| | Total liabilities | Total liabilities | $ | — | | | $ | — | | | $ | 32 | | | $ | 32 | | Total liabilities | $ | — | | | $ | — | | | $ | 26 | | | $ | 26 | |
| | | | | | | | | | | | | | | | | | | | | | | |
| December 31, 2022 |
| Level 1 | | Level 2 | | Level 3 | | Total |
Money market funds(1) | $ | 5,340 | | | $ | — | | | $ | — | | | $ | 5,340 | |
| Total assets | $ | 5,340 | | | $ | — | | | $ | — | | | $ | 5,340 | |
| | | | | | | |
| | | | | | | |
_________________
(1) Included in cash, and cash equivalents, and restricted cash on the condensed consolidated balance sheets. This balance includes cash requirements settled on a nightly basis.
There were no transfers made among the three levels in the fair value hierarchy during periods presented.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
As part of the Merger transaction, Former Elicio adopted Angion’s warrant liabilities. The following table presents a summary of changes in Level 3 in the fair value of the Company’s common stock warrant liability (in thousands):
| | | | | | | | | |
| JuneSeptember 30,
2023 | June 1,December 31,
20232022 | |
| Balance, beginning of the period | $ | — | | $ | — | | |
| Existing Angion Warrant Liability | 9 | | — | | |
| Change in fair value | 2317 | | — | | |
| Balance, end of the period | $ | 3226 | | $ | — | | |
Both observable and unobservable inputs were used to determine the fair value of positions that the Company has classified within the Level 3 category. Unrealized gains and losses associated with assets and liabilities within the Level 3 category include changes in fair value that were attributable to both observable (e.g., changes in market interest rates) and unobservable (e.g., changes in unobservable long-dated volatilities) inputs.
The fair value of the warrants issued by the Company has been estimated using a variant of Black-Scholes. The underlying equity included in Black-Scholes was valued based on the equity value implied from sales of preferred and common stock at each measurement date. The fair value of the warrants was impacted by the model selected as well as assumptions surrounding unobservable inputs including the underlying equity value, expected volatility of the underlying equity, risk free interest rate, and the expected term.
The Company records the change in the fair value of common stock warrants in change in fair value of warrant liability in the condensed consolidated statements of operations.
The fair value of the common stock warrant liability was estimated using the following assumptions:
| | | | | | | | | | | |
| September 30,
2023 | | June 1,
2023 |
| Weighted average strike price | $76.00 | | $76.00 |
| Contractual term (years) | 4.9 | | 5.2 |
| Volatility (annual) | 153.2% | | 100.0% |
| Risk-free rate | 4.6% | | 3.9% |
| Dividend yield (per share) | 0.0% | | 0.0% |
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
The fair value of the common stock warrant liability was estimated using the following assumptions:
| | | | | | | | | | | |
| June 30,
2023 | | June 1,
2023 |
| Weighted average strike price | $76.00 | | $76.00 |
| Contractual term (years) | 5.2 | | 5.2 |
| Volatility (annual) | 164.1% | | 100.0% |
| Risk-free rate | 4.1% | | 3.9% |
| Dividend yield (per share) | 0.0% | | 0.0% |
Note 5—Balance Sheet Components
Prepaid and Other Current Assets
Prepaid and other current assets consisted of the following (in thousands):
| | | June 30,
2023 | | December 31,
2022 | | September 30,
2023 | | December 31,
2022 |
| Prepaid research and development contract services | Prepaid research and development contract services | $ | 2,278 | | | $ | 2,132 | | Prepaid research and development contract services | $ | 2,379 | | | $ | 2,132 | |
| Advanced professional fees | Advanced professional fees | 241 | | | 648 | | Advanced professional fees | 209 | | | 648 | |
| Prepaid insurance | Prepaid insurance | 714 | | | 104 | | Prepaid insurance | 496 | | | 104 | |
| Return of collateral for letter of credit | 618 | | | — | | |
| | Miscellaneous receivables | Miscellaneous receivables | 557 | | | — | | Miscellaneous receivables | 102 | | | — | |
| | Other prepaid expenses and other current assets | Other prepaid expenses and other current assets | 135 | | | 36 | | Other prepaid expenses and other current assets | 233 | | | 36 | |
| Total prepaid and other current assets | Total prepaid and other current assets | $ | 4,543 | | | $ | 2,920 | | Total prepaid and other current assets | $ | 3,419 | | | $ | 2,920 | |
Property and Equipment, Net
Property and equipment, net consisted of the following (in thousands):
| | | June 30,
2023 | | December 31,
2022 | | September 30,
2023 | | December 31,
2022 |
| Equipment | Equipment | $ | 1,643 | | | $ | 1,787 | | Equipment | $ | 1,678 | | | $ | 1,787 | |
| Furniture and fixtures | Furniture and fixtures | 374 | | | 359 | | Furniture and fixtures | 374 | | | 359 | |
| Leasehold improvements | Leasehold improvements | 124 | | | 124 | | Leasehold improvements | 132 | | | 124 | |
| | Total property and equipment | Total property and equipment | 2,141 | | | 2,270 | | Total property and equipment | 2,184 | | | 2,270 | |
| Less: accumulated depreciation | Less: accumulated depreciation | (1,222) | | | (1,123) | | Less: accumulated depreciation | (1,412) | | | (1,123) | |
| Property and equipment, net | Property and equipment, net | $ | 919 | | | $ | 1,147 | | Property and equipment, net | $ | 772 | | | $ | 1,147 | |
Depreciation expense for each of the three and sixnine months ended JuneSeptember 30, 2023 was immaterial and $0.3 million, respectively. Depreciation expense for the three and nine months ended September 30, 2022 was immaterial.$0.1 million and $0.3 million, respectively.
Other long-term prepaid assets
Other long-term prepaid assets consisted of the advance payments for clinical trial services, totaling $2.8 million for both periods ending Juneas of September 30, 2023 and December 31, 2022, respectively.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
Accrued Expenses
Accrued expenses consisted of the following (in thousands):
| | | June 30,
2023 | | December 31,
2022 | | September 30,
2023 | | December 31,
2022 |
| Accrued professional fees | Accrued professional fees | $ | 709 | | | $ | 180 | | Accrued professional fees | $ | 951 | | | $ | 180 | |
| Accrued compensation and benefits | Accrued compensation and benefits | 1,489 | | | 1,491 | | Accrued compensation and benefits | 1,577 | | | 1,491 | |
| Accrued research and development | Accrued research and development | 112 | | | 260 | | Accrued research and development | 1,875 | | | 260 | |
| Other operating expenses | 5 | | | 4 | | |
| Other accrued expenses | | Other accrued expenses | 13 | | | 4 | |
| Total accrued expenses | Total accrued expenses | $ | 2,315 | | | $ | 1,935 | | Total accrued expenses | $ | 4,416 | | | $ | 1,935 | |
Note 6 — Research Grant
In September 2022, Former Elicio entered into a grant agreement with Thethe Gastro-Intestinal (“GI”) Research Foundation, (“GIRF”), a not-for-profit organization focused on supporting research to treat, cure and prevent digestive
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
diseases. Of the $2.8 million award, $2.3 million was received in September 2022 and the remaining $0.5 million was received in June 2023 with the completion of the development efforts as defined in the agreement.
For the three and sixnine months ended JuneSeptember 30, 2023, the Company incurred $1.4 millionzero and $1.9 million respectively, in research and development expenses related to this project. For both the three and nine months ended September 30, 2022, the Company incurred $0.1 million in research and development expenses related to this project.
In September 2023, the Company entered into a second grant agreement with the GI Research Foundation for $3.1 million, with such amount received net of a $0.5 million credit. The grant funds available as of September 30, 2023 are $1.7 million, which are reflected in restricted cash and the deferred research obligation in the accompanying consolidated balance sheets. For the three and nine months ended September 30, 2023 the Company incurred $1.4 million in research and development expenses related to this project.
The award money for both agreements was earned and recognized as a contra research and development expense as the expenses were incurred.
Note 7—Convertible Preferred Stock, Common Stock and Stockholders' Equity
Authorized Shares
The Company's current Amended and Restated Certificate of Incorporation, as amended, authorizes 300,000,000 shares of common stock, par value $0.01 per share, and 10,000,000 shares of preferred stock, par value $0.01 per share.
Convertible Preferred Stock
Former Elicio’s convertible preferred stock consisted of Series A preferred stock (“Series A Preferred Shares”), Series B preferred stock (“Series B Preferred Shares”) and Series C preferred stock (“Series C Preferred Shares”).
Series C Convertible Preferred Stock
In May 2022, Former Elicio authorized the sale and issuance of up to 760,200 shares of $0.06 par value Series C Preferred Shares at an original issuance price of $66.30 per share and up to 325,800 shares of Series C Preferred for the settlement of the Convertible Notes Payable. The Series C Preferred Shares financing was structured to be issued in rolling closes in 2022.
From the period May through JuneSeptember 2022, Former Elicio issued 103,637772,579 shares of Series C Preferred Shares for gross proceeds of approximately $1.5$11.0 million. Former Elicio incurred cash issuance costs of approximately $0.3$1.0 million in connection with these shares.
Conversion of Convertible Preferred Stock
On June 1, 2023, Former Elicio completed the Merger with Angion in accordance with the Merger Agreement. Under the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each share of Former Elicio’s preferred stock was converted into a share of Former Elicio’s common stock. At the closing of the merger,Merger, the Company issued an aggregate of 5,375,751 shares of its common stock to Former Elicio stockholders, based on an exchange ratio of 0.0181 shares of the Company’s common stock for each share of Former Elicio’s common stock outstanding immediately prior to the Merger, including those shares of common stock issued upon
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
conversion of the Former Elicio preferred stock. No shares and 103,637772,579 shares of convertible preferred stock were issued during the sixnine months ended JuneSeptember 30, 2023 and 2022, respectively.
The authorized, issued and outstanding shares of the convertible preferred stock and liquidation preferences of Former Elicio as of December 31, 2022 were as follows (in thousands, except share and per share amounts):
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
| | | | | | | | | | | | | | | |
| Authorized Shares | Shares Issued and Outstanding | | Aggregate Liquidation Amount | Proceeds Net of Liquidation Costs |
| Series A Convertible Preferred Shares | 132,387 | | 132,387 | | | $7,495 | $7,495 |
| Series B Convertible Preferred Shares | 1,927,375 | | 1,927,375 | | | $72,803 | $62,944 |
| Series C Convertible Preferred Shares | 4,888,798 | | 2,938,158 | | | $41,816 | $40,621 |
| Total Preferred Shares | 6,948,560 | | 4,997,920 | | | | |
The Series A and Series B Preferred Shares were deemed changed as of October 18, 2022 into 132,387 and 1,927,375 preferred shares (retroactively restated for the reverse recapitalization as described in Note 3) due to the antidilutive protection triggered by the Series C shares issued in October 2022 at a price below $1.00.
As a result of the Merger, the aggregate amount of 4,997,920 shares of Former Elicio preferred stock (retroactively restated for the reverse recapitalization as described in Note 3) were converted into 4,997,920 outstanding shares of Former Elicio's common stock to be exchanged for the same number of shares of the Company’s common stock.
Note 8—Stock-Based Compensation
2012 Plan and 2022 Plan
Pursuant to the Merger Agreement, the Company assumed the Former Elicio 2022 Equity Incentive Plan and the Former Elicio 2012 Equity Incentive Plan (the “Former Elicio Plans”) and all stock options issued and outstanding under the Former Elicio Plans and eachPlans. Each outstanding and unexercised option to purchase Former Elicio common stock was adjusted with such Company stock options henceforth representing the right to purchase a number of shares of the Company’s common stock.stock based on an exchange ratio of 0.0181. Any restriction on the exercise of any Former Elicio stock option assumed by the Company will continue in full force and effect and the term, exercisability, vesting schedule, accelerated vesting provisions, and any other provisions of such Former Elicio stock option will otherwise remain unchanged; provided, however, that the Company’s board of directors or a committee thereof will succeed toassume the authorityresponsibility and responsibilitythe authority of Former Elicio’s board of directors or any committee thereof with respect to each Former Elicio stock option assumed by the Company.
2015 Plan
In June 2019, Angion approved an Amended and Restated 2015 Equity Incentive Plan (the “2015 Plan”) permitting the granting of incentive stock options, non-statutory stock options, restricted stock and other stock-based awards. Following the effectiveness of the 2021 Equity Incentive Plan (“2021 Plan”), the Company ceased making grants under the 2015 Plan. However, the 2015 Plan continues to govern the terms and conditions of the outstanding awards granted under it. Shares of common stock subject to awards granted under the 2015 Plan that cease to be subject to such awards by forfeiture or otherwise after the termination of the 2015 Plan will be available for issuance under the 2021 Plan.
2021 Plan and Amendment to 2021 Plan
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
On January 25, 2021, Angion’s board of directors approved the 2021 Plan (“2021 Plan”) which permits the granting of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units and other stock-based awards to employees, directors, officers and consultants. The 2021 Plan provides that the number of shares reserved and available for issuance will automatically increase each January 1 by the lesser of 5% of the Company’s common stock outstanding on the immediately preceding December 31, or such lesser number of shares as determined by the Company’s board of directors. On March 17, 2023, Angion’s board of directors approved an amendment to the 2021 Plan to increase the cumulative number of shares of common stock reserved for issuance thereunder by 30,113 shares.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
As of JuneSeptember 30, 2023, 566,844570,271 shares under the 2021 Planand 91,707 shares remain available for future grants.
Stock Options
The following table summarizes information and activity related to the Company’s stock options:
| | | Number of
Stock Options | | Weighted Average
Exercise Price | | Weighted Average
Remaining Contractual Life
(in years) | | Total
Intrinsic Value
(in thousands) | | Number of
Stock Options | | Weighted Average
Exercise Price | | Weighted Average
Remaining Contractual Life
(in years) | | Total
Intrinsic Value
(in thousands) |
| Outstanding as of December 31, 2022 | Outstanding as of December 31, 2022 | 854,076 | | | $ | 5.24 | | | 7.72 | | $ | — | | Outstanding as of December 31, 2022 | 854,076 | | | $ | 5.24 | | | 7.72 | | $ | — | |
| Options granted | Options granted | 135,526 | | | 10.00 | | | Options granted | 186,572 | | | 9.96 | | |
| Existing Angion Options outstanding | Existing Angion Options outstanding | 351,656 | | | 62.04 | | | Existing Angion Options outstanding | 351,656 | | | 61.99 | | |
| Options exercised | Options exercised | (35,709) | | | 6.99 | | | Options exercised | (61,791) | | | 10.08 | | |
| Forfeited (unvested) | Forfeited (unvested) | (20,292) | | | 30.96 | | | Forfeited (unvested) | (19,579) | | | 33.97 | | |
| Outstanding as of June 30, 2023 | 1,285,257 | | | $ | 20.62 | | | 7.68 | | $ | 3,509 | | |
| Outstanding as of September 30, 2023 | | Outstanding as of September 30, 2023 | 1,310,934 | | | $ | 19.99 | | | 7.68 | | $ | 2,841 | |
| Options vested and exercisable | Options vested and exercisable | 558,512 | | | $ | 41.00 | | | 5.59 | | $ | 586 | | Options vested and exercisable | 597,723 | | | $ | 38.50 | | | 5.59 | | $ | 645 | |
The aggregate intrinsic value in the above table is calculated as the difference between the estimated fair value of the Company's common stock price and the exercise price of the stock options. 135,526186,572 stock options were granted in the sixnine months ended JuneSeptember 30, 2023. The weighted average grant date fair value per share for the stock option grants during the sixnine months ended JuneSeptember 30, 2023 was $10.00.$9.96. As of JuneSeptember 30, 2023, the total unrecognized compensation related to unvested stock option awards granted was $2.7 million, which the Company expects to recognize over a weighted-average period of approximately 1.41.64 years.
Stock-based Compensation Expense
The following table summarizes total stock-based compensation expense recorded in the condensed consolidated statements of operations (in thousands):
| | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | Three Months Ended
September 30, | | Nine Months Ended
September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 |
| Research and development | Research and development | $ | 229 | | | $ | 71 | | | $ | 412 | | | $ | 132 | | Research and development | $ | 13 | | | $ | 68 | | | $ | 425 | | | $ | 200 | |
| General and administrative | General and administrative | 50 | | | 42 | | | 91 | | | 138 | | General and administrative | 326 | | | 42 | | | 417 | | | 180 | |
| Total | Total | $ | 279 | | | $ | 113 | | | $ | 503 | | | $ | 270 | | Total | $ | 339 | | | $ | 110 | | | $ | 842 | | | $ | 380 | |
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
The fair value of each option is estimated on the date of grant using Black-Scholes with the assumptions noted in the table below. The fair value of an award with only a service condition is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which is generally the vesting period. Compensation cost of awards that contain a performance condition are recognized when success is considered probable during the performance period. The Company has elected to account for forfeitures as they occur, rather than estimating the number of awards that are expected to vest. The risk-free interest rate is estimated using the weighted average rate of return on U.S. Treasury notes with a life that approximates the expected life of the option. The expected term of options granted to employees was calculated using the simplified method, which represents the average of the contractual term of the option and the weighted-average vesting period of the option. The Company uses the simplified method because it does not have sufficient historical option exercise data to provide a reasonable basis upon which to estimate expected term. The contractual life of the option was used for the expected life of options granted to non-employees. Expected volatility is based on the weighted average of the historical volatility of a peer group of publicly traded companies. The assumed dividend yield is based upon the Company's expectation of not paying dividends in the foreseeable future.
The fair value of each employee and non-employee stock option grant was estimated on the date of grant using Black-Scholes based on the following assumptions.
| | Options | Options | Three months ended June 30, | | Six months ended June 30, | Options | Three months ended September 30, | | Nine months ended September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 |
| Risk-free interest rate | Risk-free interest rate | 3.7% | | 2.3% | | 3.7% | | 2.3% | Risk-free interest rate | 4.4% | | 2.3% | | 3.7% | | 2.3% |
| Expected dividend yield | Expected dividend yield | 0.0% | | 0.0% | | 0.0% | | 0.0% | Expected dividend yield | 0.0% | | 0.0% | | 0.0% | | 0.0% |
| Expected term in years (employees) | Expected term in years (employees) | 6.00 | | 6.54 | | 6.00 | | 6.54 | Expected term in years (employees) | 6.06 | | 6.54 | | 6.00 | | 6.54 |
| Expected volatility | Expected volatility | 71.9% - 72.5% | | 60.3% - 62.1% | | 71.9% - 72.5% | | 60.3% - 62.1% | Expected volatility | 71.7% - 72.1% | | 60.3% - 62.1% | | 71.9% - 72.5% | | 60.3% - 62.1% |
In March 2021 and June 2022, certain employees of the Company early exercised options to purchase shares of Common Stock.the Company’s common stock. The shares had not fully vested at the time of exercise and were recorded as an unvested option exercise liability. As the shares vest, the Company recognizes the shares and related expense as issuance of common stock upon settlement of restricted stock on the Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the periods ended JuneSeptember 30, 2023 and December 31, 2022.
Employee Stock Purchase Plan
In January 2021, the board of directors of Angion approved the Employee Stock Purchase Plan (the “ESPP”). The ESPP was effective on the date immediately prior to the effectiveness of the Angion's registration statement relating to the IPO. The offering period and purchase period was determined by theAngion’s board of directors. Pursuant to the Merger Agreement, the Company assumed the ESPP. No offering periods or purchasing periods were active as of JuneSeptember 30, 2023. As of JuneSeptember 30, 2023, 68,958 shares under the ESPP remain available for purchase and no offerings have been authorized.
Restricted Stock Units
In March 2021, the CompanyFormer Elicio granted an employee restricted stock units (RSUs)(“RSUs”) with service and performance vesting conditions.conditions to an employee. The completion of the Merger satisfied the performance vesting criteria and triggered accelerated vesting for all unvested RSUs. As a result, the employee received 41,005 shares on June 1, 2023. To pay for the tax withholdings that were due upon vesting of the RSUs, the employee sold 14,455 shares to the Company, which are held in treasury stock as of JuneSeptember 30, 2023.
Note 9—Warrants
In accordance with ASC 815, the warrants classified as liabilities are recorded at fair value at the issuance date, with changes in the fair value recognized in the condensed consolidated statements of operations at the end of each reporting period. Refer to Note 4 for changes in the fair value recognized during the periods reported.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
In accordance with ASC 815, the warrants classified as equity do not meet the definition of a derivative and are classified in stockholders' equity in the condensed consolidated balance sheets.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
There was no warrant activity during the sixnine months ended JuneSeptember 30, 2023, other than the assumption of the previously issued Angion warrants by the Company.
The following table summarizes information regarding Common Stockcommon stock warrants outstanding at JuneSeptember 30, 2023:
| | | Warrants | | Weighted
Average
Exercise
Price | Weighted Average Life (years) | | Warrants | | Weighted
Average
Exercise
Price | Weighted Average Life (years) |
| Outstanding at December 31, 2022 | Outstanding at December 31, 2022 | 144,814 | | | $ | 53.59 | | 6.5 | Outstanding at December 31, 2022 | 144,814 | | | $ | 53.59 | | 6.5 |
| | Angion Warrants assumed | Angion Warrants assumed | 3,950 | | | 76.00 | | 5.2 | Angion Warrants assumed | 3,950 | | | 76.00 | | 4.9 |
| Outstanding at June 30, 2023 | 148,764 | | | $ | 54.19 | | 6.5 | |
| Outstanding at September 30, 2023 | | Outstanding at September 30, 2023 | 148,764 | | | $ | 54.19 | | 6.5 |
Note 10—Commitments and Contingencies
Operating Leases
In July 2021, the Company signed an operating lease for office and laboratory space in Boston, Massachusetts (the “Boston Lease”). The Boston lease commenced in February 2022 with the term set to expire in January 2030. The lease has rent payments escalating annually, which totalstotal $11.1 million.million in the aggregate. As a result, at the commencement of the lease the Company recognized a right-of-use lease asset of $8.0 million with a corresponding lease liability of $8.0 million based on the present value of the minimum rental payments. In addition, the Company will make payments for operating expenses and real estate taxes. In June 2023, the Company changed the bank that secured thea letter of credit for the deposit on the lease and has a deposit in the amount of $0.7 million, which was reported as Restricted Cash on the condensed consolidated balance sheets as of JuneSeptember 30, 2023 and December 31, 2022.
As part of the Merger Agreement, the Company also assumed a lease for clinical and regulatory space in Newton, Massachusetts (the “Newton lease”), comprising approximately 6,157 square feet for approximately $0.2 million per year, under a non-cancelable operating lease through June 30, 2024.
Lease expense for all leases for the three and sixnine months ended JuneSeptember 30, 2023 was $0.3$0.4 million and $0.7$1.1 million, respectively, and $0.3 million and $0.50.9 million, for the three and sixnine months ended JuneSeptember 30, 2022, respectively. All expenses are included in operating expenses in the accompanying condensed consolidated statements of operations and comprehensive loss.
The following table summarizes quantitative information about the Company's operating leases (dollars in thousands):
| | | Six Months Ended
June 30, | | Nine Months Ended
September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
| Operating cash flows from operating leases | Operating cash flows from operating leases | $ | 648 | | | $ | 489 | | Operating cash flows from operating leases | $ | 1,002 | | | $ | 798 | |
| Right-of-use assets exchanged for operating lease liabilities | Right-of-use assets exchanged for operating lease liabilities | $ | — | | | $ | 8,017 | | Right-of-use assets exchanged for operating lease liabilities | $ | — | | | $ | 8,017 | |
| Weighted-average remaining lease term—operating leases (in years) | Weighted-average remaining lease term—operating leases (in years) | 5.9 | | 7.0 | Weighted-average remaining lease term—operating leases (in years) | 6.2 | | 7.3 |
| Weighted-average discount rate—operating leases | Weighted-average discount rate—operating leases | 7.9 | % | | 8.0 | % | Weighted-average discount rate—operating leases | 7.7 | % | | 8.0 | % |
As of JuneSeptember 30, 2023, maturities of lease liabilities were as follows (in thousands):
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
| | Year Ended December 31, | Year Ended December 31, | | Amounts | Year Ended December 31, | | Amounts |
| | 2023 (remaining six months) | | $ | 751 | | |
| 2023 (remaining three months) | | 2023 (remaining three months) | | $ | 375 | |
| 2024 | 2024 | | 1,427 | | 2024 | | 1,427 | |
| 2025 | 2025 | | 1,349 | | 2025 | | 1,349 | |
| 2026 | 2026 | | 1,383 | | 2026 | | 1,383 | |
| 2027 | 2027 | | 1,425 | | 2027 | | 1,425 | |
| Thereafter | Thereafter | | 3,232 | | Thereafter | | 3,232 | |
| Total | Total | | 9,567 | | Total | | 9,191 | |
| Less present value discount | Less present value discount | | (2,163) | | Less present value discount | | (2,038) | |
| Operating lease liabilities | Operating lease liabilities | | 7,404 | | Operating lease liabilities | | 7,153 | |
| Less: operating lease liability, current portion | Less: operating lease liability, current portion | | (985) | | Less: operating lease liability, current portion | | (938) | |
| Operating lease liability, noncurrent portion | Operating lease liability, noncurrent portion | | $ | 6,419 | | Operating lease liability, noncurrent portion | | $ | 6,215 | |
Legal Proceedings
From time to time, the Company may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of its business or otherwise. Following announcement of the Merger Agreement with the Company on January 17, 2023, and the filing of a Registration Statement on Form S-4 on February 13, 2023, a lawsuit was filed in the United States District Court for the Eastern District of New York on February 17, 2023 by a purported stockholder of Angion in connection with the proposed merger between Angion and the Company. The lawsuit was captioned Klein v. Angion Biomedica Corp., et al., No. 1:23-cv-01313 (E.D.N.Y.). The Klein complaint named as defendants Angion, and the members of the Angion Board. The Klein complaint alleged claims for violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder against all defendants, and violations of Section 20(a) of the Exchange Act against the members of the Angion Board. The plaintiff contended that the registration statement on Form S-4 initially filed with the SEC on February 13, 2023 omitted or misrepresented material information regarding the proposed merger between Angion and the Company, rendering the registration statement false and misleading. The Klein complaint sought injunctive and declaratory relief, as well as damages. On February 21, 2023, the plaintiff filed a notice of voluntary dismissal of the Klein lawsuit. Although the plaintiffs voluntarily dismissed this case, litigation of this type is prevalent in mergers involving public companies, and other potential plaintiffs may file lawsuits challenging the Merger.
The outcome of any additional future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to the Company, including any costs associated with the indemnification of directors and officers.
The Company may be exposed to litigation in connection with its products under development and operations. The Company’s policy is to assess the likelihood of any adverse judgments or outcomes related to legal matters, as well as ranges of probable losses. The Company is not aware of any material legal matters.
License Agreements
In July 2012 and January 2016, Former Elicio licensed certain intellectual property from a university. The license term for both licenses extends until terminated by either party under certain provisions. The Company is required to pay certain contractual maintenance and milestone payments related to clinical trials and royalties on product sales over the term of the contract, with minimum annual royalty payments commencing in the calendar year after commercialization. In January 2019, Former Elicio licensed additional intellectual property and terminated a license obtained in July 2012 from the university. No commercialization royalties have been achieved.
Future minimum annual maintenance payments are $0.1 million for the year ended December 31, 2023 and for each year thereafter. Future minimum annual payments are due until the termination of the agreement.
Note 11—Income Taxes
The Company did not record a provision or benefit for income taxes during the three and sixnine months ended JuneSeptember 30, 2023 and 2022. As of JuneSeptember 30, 2023 and December 31, 2022, the Company continues to maintain a full valuation allowance against all of its deferred tax assets in light of its history of cumulative net losses.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
Note 12—Net Loss Per Share
The Company has reported losses since inception and has computed basic net loss per share attributable to common stockholders by dividing net loss attributable to common stockholders by the weighted-average number of shares of Common Stockcommon stock outstanding for the period, without consideration for potentially dilutive securities. The Company computes diluted net loss per share of Common Stockcommon stock after giving consideration to all potentially dilutive shares of Common Stock,common stock, including options to purchase Common Stockcommon stock and Preferred Stock,preferred stock, outstanding during the period determined using the treasury-stock and if-converted methods, except where the effect of including such securities would be antidilutive. Because the Company has reported net losses since inception, these potential shares of Common Stockcommon stock and Preferred Stockpreferred stock have been anti-dilutive and basic and diluted loss per share were the same for all periods presented.
Table of Contents
ELICIO THERAPEUTICS, INC.
Notes to Unaudited Interim Condensed Consolidated Financial Statements (Continued)
Basic and diluted net loss per share attributable to common stockholders was calculated at JuneSeptember 30, as follows (in thousands, except share and per share data):
| | | Three Months Ended
June 30, | | Six Months Ended
June 30, | | Three Months Ended
September 30, | | Nine Months Ended
September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 | | 2023 | | 2022 |
| Numerator | Numerator | | | | | | | | Numerator | | | | | | | |
| Net loss | Net loss | $ | (7,559) | | | $ | (7,299) | | | $ | (15,586) | | | $ | (14,359) | | Net loss | $ | (10,658) | | | $ | (7,198) | | | $ | (26,246) | | | $ | (21,557) | |
| Denominator: | Denominator: | | | | | | | | Denominator: | | | | | | | |
| Weighted-average shares used in computing net loss per share, basic and diluted | Weighted-average shares used in computing net loss per share, basic and diluted | 3,100,957 | | 314,572 | | 1,720,202 | | 313,148 | Weighted-average shares used in computing net loss per share, basic and diluted | 8,376,384 | | 317,512 | | 8,240,326 | | 314,619 |
| Net loss per share, basic and diluted | Net loss per share, basic and diluted | $ | (2.44) | | | $ | (23.20) | | | $ | (9.06) | | | $ | (45.85) | | Net loss per share, basic and diluted | $ | (1.27) | | | $ | (22.67) | | | $ | (3.19) | | | $ | (68.52) | |
The table below provides potentially dilutive securities not included in the calculation of the diluted net loss per share because to do so would be anti-dilutive:
| | | Six Months Ended
June 30, | | Nine Months Ended
September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
| Convertible preferred stock | Convertible preferred stock | — | | | 2,059,762 | | Convertible preferred stock | — | | | 2,180,699 | |
| Shares issuable upon exercise of stock options | Shares issuable upon exercise of stock options | 1,285,257 | | 8,515 | Shares issuable upon exercise of stock options | 2,836 | | 7,582 |
| Shares issuable upon the exercise of warrants | Shares issuable upon the exercise of warrants | 148,764 | | 127,982 | Shares issuable upon the exercise of warrants | 148,764 | | 144,815 |
| Options to purchase Common Stock | Options to purchase Common Stock | — | | 250,288 | Options to purchase Common Stock | 1,310,934 | | 224,319 |
| | Total | Total | 1,434,021 | | 2,446,547 | Total | 1,462,534 | | 2,557,415 |
Note 13—Related Party Transactions
The Company paid $0.3$0.1 million and $0.7 million for the three and sixnine months ended JuneSeptember 30, 2023, respectively, and $0.1 million and $0.2 million for the three and sixnine months ended JuneSeptember 30, 2022, respectively, for consulting services provided by an entity affiliated with the Company’s former interim chief financial officer and former board member.
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and the related notes appearing elsewhere in this Quarterly Report on Form 10-Q and in our audited financial statements and accompanying notes for the year ended December 31, 2022 and 2021 included in our proxy statement/prospectus/information statement on Form S-4 filed April 26, 2023, as amended (the “Form S-4”). In addition to the historical financial information, this discussion contains forward-looking statements involving risks, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions, forecasts and projections. Our actual results and the timing of selected events could differ materially from those discussed in these forward-looking statements as a result of several factors, including those set forth under the section of this Quarterly Report on Form 10-Q titled “Risk Factors,”Factors” and the Current Report on Form 8-K filed on June 2, 2023, which you should read carefully to gain an understanding of the important factors that could cause actual results to differ materially from our forward-looking statements. Please also see the section titled “Forward-Looking Statements” at the beginning of this report.
Overview
We are a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. For therapies designed to engage the immune system to treat disease, it is critical to target activation to lymph nodes where adaptive immune responses are generated. Our proprietarycancer. Through our Amphiphile, or AMP, platform delivers immunotherapeutics directlytechnology, our goal is to re-engineer the body’s immune response to defeat diseases using potent lymph node targeted vaccines and immunotherapies.
Our proprietary AMP technology precisely traffics immuno-modulatory molecules to the lymph nodes. We believe this site-specific deliverynodes, the “schoolhouse” of disease-specific antigens, adjuvants,the immune system, enhancing the magnitude, potency, functionality, and other immunomodulators will more efficiently educate, activate, and amplify criticaldurability of the immune response. The lymph nodes are a primary site in the body where most immune cells resultingare located. The lymph nodes are where the immune system naturally collects information about health and disease in inductionorder to orchestrate the mechanisms of immunity which protect us from pathogens and persistencetumors. By efficiently targeting these sites within the body we are taking advantage of potent adaptive immunity requiredthe power and the unique biology of the lymph nodes to improve responses across a broad range of diseases. We are utilizing our lymph-node targeting technology to build a pipeline of therapeutic cancer vaccines, which will be the focus of the company.
Our core business is the development of therapeutic cancer vaccines. ELI-002, our lead clinical program, is designed to stimulate an immune response against the KRAS mutations driving 25% of solid tumors. ELI-002 2P, our 2-peptide formulation designed to treat many diseases. Our lead product candidate, ELI-002,cancers driven by G12D and G12R mutations in KRAS, is currently being studied in an ongoing phase 1 trials(AMPLIFY-201) trial in patients with initialmutant (m)KRAS-driven pancreatic ductal adenocarcinoma (“PDAC”) and colorectal cancer. Initial data for ELI-002 2P was presented at the 2023 American Society of Clinical Oncology (ASCO)(“ASCO”) Annual Meeting.Meeting and additional preliminary data including relapse-free survival data was presented at the 2023 AACR Special Conference on Pancreatic Cancer. We presented updated preliminary immunogenicity data from the ongoing phase 1 study of ELI-002 2P at the Society for Immunotherapy of Cancer 38th Annual Meeting (“SITC 2023”). ELI-002 7P, our 7-peptide formulation, is currently being studied in AMPLIYFY-7P, a phase 1/2 trial in patients with high relapse risk mKRAS-driven solid tumors. The AMPLIYFY-7P study’s independent data monitoring committee supported initiation of a randomized phase 2 trial studying ELI-002 7P as a monotherapy in adjuvant PDAC patients, which we plan to initiate in early 2024.
Our operations through June 1, 2023to date have been financed primarily by aggregate net proceeds of $89.1$99.6 million from the issuance of convertible preferred stock, convertible notes, and the exercise of stock options and common stock warrants. Since inception, we have had significant annual operating losses. Our net loss was $7.6$10.7 million and $7.3$7.2 million for the three months ended JuneSeptember 30, 2023 and 2022, respectively, and $15.6$26.2 million and $14.4$21.6 million for the sixnine months ended JuneSeptember 30, 2023 and 2022, respectively. As of JuneSeptember 30, 2023, we had an accumulated deficit of $122.6$133.3 million and $21.7$14.8 million in cash and cash equivalents.
Elicio Operating Company, Inc. (formerly known as “Elicio Therapeutics, Inc.”(“Former Elicio”) was incorporated in Delaware as Vedantra Pharmaceuticals Inc. in August 2011. In December 2018, Former Elicio formed a wholly owned subsidiary, Elicio Securities Corporation, a Massachusetts corporation.
On January 17, 2023, Former Elicio entered into a definitive merger agreement (the “Merger Agreement”) with Angion Biomedica Corp (“Angion”), a clinical-stage biotechnology company. In accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, by and among Angion, Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (“Merger Sub”), and Former Elicio, pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the “Merger”).
On June 1, 2023, the Merger was completed in accordance with the terms and conditions of the Merger Agreement and Angion changed its name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.” Immediately following the consummation of the Merger, there were approximately 9.7 million shares of our common stock outstanding on a fully-diluted basis, with Former Elicio equity holders collectively owning approximately65.2% of the Company and Angion equity holders collectively owning approximately34.8%of the Company, in each case on a fully diluted basis.
We are currently facing substantial doubt about our ability to continue as a going concern, given our cash position and cash runway. We believe that our cash on hand will enable us to fund our operations into the first quarter of calendar year 2024 based on our current plan. This period could be shortened if there are any significant increases in planned or actual spending on development programs or more rapid progress of development programs than anticipated. There is no assurance that financing will be available when needed to allow us to continue as a going concern. Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the unaudited condensed consolidated financial statements, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. We plan to address this condition through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions, but there is no assurance these plans will be completed successfully or at all.If we are unable to obtain additional capital when and as needed to continue as a going concern, we might have to further reduce or scale back our operations and/or liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our financial statements.
Our unaudited condensed consolidated financial statements appearing elsewhere in this 10-Q statement have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. Our unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern.
Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our accounts payable and accrued expenses. We expect to continue to incur net losses for the foreseeable future, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. In particular, we expect our expenses to increase as we continue our development of, and seek regulatory approvals for, our product candidates, as well as hire additional personnel, pay fees to outside consultants, attorneys and accountants, and incur other increased costs associated with being a public company. In addition, if and when we seek and obtain regulatory approval to commercialize any product candidate, we will also incur increased expenses in connection with commercialization and marketing of any such product. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase significantly in connection with our ongoing activities, as we:
• advance our lead product candidate, ELI-002, to late stage clinical trials;
• advance our preclinical programs to clinical trials;
• expand our pipeline of product candidates;
• seek regulatory approval for our investigational medicines;
• maintain, expand, protect and defend our intellectual property portfolio;
• acquire or in-license technology;
• expand our clinical, scientific, management and administrative teams; and
• operate as a public company.
We believe that our cash on hand will enable us to fund our operations throughinto the first quarter of calendar year 20232024 based on our current plan. We have based this estimate on assumptions that may prove to be wrong, and we
could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. The Company’s losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the unaudited condensed consolidated financial statements, raise substantial doubt about the Company’s ability to continue as a going concern.
We have not had any products approved for sale. We do not expect to generate any product sales unless and until we successfully complete development and obtain regulatory approval for one or more of our product candidates. If we obtain regulatory approval for any of our product candidates, we expect to incur significant commercialization expenses related to product sales, marketing, manufacturing and distribution. As a result, until such time, if ever, that we can generate substantial product revenue, we expect to finance our cash needs through equity offerings, debt financings or other capital sources, including collaborations, licenses or similar arrangements. However, we may be unable to raise additional funds or enter into such other arrangements when needed or on favorable terms, if at all. Any failure to raise capital as and when needed could have a negative impact on our financial condition and on our ability to pursue our business plans and strategies, including our research and development activities. If we are unable to raise capital, we will need to delay, reduce or terminate planned activities to reduce costs.
On January 17, 2023, we entered into a definitive merger agreement (the “Merger Agreement”) with Angion Biomedica Corp (“Angion”), a clinical-stage biotechnology company. In accordance with the terms and conditions of the Agreement and Plan of Merger and Reorganization, by and among Angion, Arkham Merger Sub, Inc., a wholly owned subsidiary of Angion (“Merger Sub”), and Elicio Therapeutics, Inc. (“Former Elicio”), pursuant to which Merger Sub merged with and into Former Elicio, with Former Elicio surviving the merger as a wholly owned subsidiary of Angion (the “Merger”).
On June 1, 2023, we completed the Merger in accordance with the terms and conditions of the Merger Agreement and changed our name from “Angion Biomedica Corp.” to “Elicio Therapeutics, Inc.” Immediately following the consummation of the Merger, there were approximately 9.7 million shares of our common stock outstanding on a fully-diluted basis, with Former Elicio equity holders collectively owning approximately 65.2% of Elicio and Angion equity holders collectively owning approximately 34.8% of Elicio, in each case on a fully diluted basis.
Components of Results of Operations
The following discussion summarizes the key factors our management believes are necessary for an understanding of our financial statements.
Operating Expenses
Our operating expenses since inception have consisted primarily of research and development expenses and general and administrative costs.
Research and Development Expenses
Our research and development expenses consist primarily of costs incurred for the development of our product candidates and our drug discovery efforts, which include:
• personnel costs, which include salaries, benefits and equity-based compensation expense;
• expenses incurred under agreements with consultants and contract organizations that conduct research and
development activities on our behalf;
• costs related to sponsored research service agreements;
• costs related to production of preclinical and clinical materials, including fees paid to contract manufacturers;
• laboratory and vendor expenses related to the execution of preclinical studies and planned clinical trials; and
• laboratory supplies and equipment used for internal research and development activities.
We expense all research and development costs in the periods in which they are incurred. Costs for certain research and development activities are recognized based on an evaluation of the progress to completion of specific tasks using information and data provided to us by our vendors and service providers.
Our research and development expenses are not currently tracked on a program-by-program basis. We use our personnel and infrastructure resources across multiple research and development programs directed toward identifying and developing product candidates. Substantially all our research and development costs are incurred on the development of ELI-002 and ELI-004, an AMP adjuvant that is a significant component of ELI-002, and our preclinical candidates.
We expect our research and development expenses to increase substantially for the foreseeable future as we continue to invest in research and development activities related to developing our product candidates, including investments in conducting clinical trials, manufacturing and otherwise advancing our programs. The process of conducting the clinical research necessary to obtain regulatory approval is costly and time-consuming, and the successful development of our product candidates is highly uncertain. At this time, we cannot reasonably estimate the nature, timing and costs of the efforts that will be needed to complete the development of, or the period, if any, in which material net cash inflows may commence from ELI-002 or any of our preclinical candidates. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:
•the scope, rate of progress and expense of our research and development activities;
•clinical trials and early-stage results;
•the terms and timing of regulatory approvals; and
•the ability to market, commercialize and achieve market acceptance for ELI-002, or any of our preclinical candidates that we or our future collaboration partners may develop in the future.
Any of these variables with respect to the development of ELI-002, or any other of our preclinical candidates that we may develop could result in a significant change in the costs and timing associated with the development of such candidates. For example, if the FDA or other regulatory authority were to require us to conduct pre-clinical and clinical studies beyond those which we currently anticipate will be required for the completion of clinical development or if we experience significant delays in enrollment in any clinical trials, we could be required to expend significant additional financial resources and time on the completion of our clinical development programs.
General and Administrative Expenses
Our general and administrative expenses consist primarily of personnel costs, including equity-based compensation, and other expenses for outside professional services, including legal, recruiting, audit and accounting and facility-related costs not otherwise included in research and development expenses. Personnel costs consist of salaries, benefits and equity-based compensation expense, for our personnel in executive and other administrative functions. We expect our general and administrative expenses to increase over the next several years to support our continued research and development activities, manufacturing activities, increased costs of expanding our operations and operating as a public company. These increases will likely include increases related to the hiring of additional personnel and legal, regulatory and other fees and services associated with maintaining compliance with Nasdaq Stock Market LLC or Nasdaq,(“Nasdaq”), Marketplace Rules, or the Nasdaq Listing Rules and Securities and Exchange Commission or SEC,(“SEC”) requirements, accounting and audit fees, director and officer insurance costs and investor relations costs associated with being a public company.
Other Income (Expense)
For the three and sixnine months ended JuneSeptember 30, 2023 and 2022, other income and expense consisted primarily of interest income, foreign exchange transaction gains,losses, loss on sale of equipment, interest expense, changes in fair value of the embedded derivative, gain and loss from the settlementon extinguishment of promissory notes, and gains and losses related to the re-measurement of our warrant liabilities.
Results of Operations
Comparison of the Three Months Ended JuneSeptember 30, 2023 and 2022
The following table summarizes our results of operations for the periods indicated:
| | | Three Months Ended
June 30, | | | Three Months Ended
September 30, | |
| | 2023 | | 2022 | | $ Change | | % Change | | 2023 | | 2022 | | $ Change | | % Change |
| | (In thousands, except percentages) | | (In thousands, except percentages) |
| Operating expenses: | Operating expenses: | | | | | Operating expenses: | | | | |
| Research and development | Research and development | $ | 4,944 | | | $ | 5,041 | | | $ | (97) | | | (2) | % | Research and development | $ | 7,264 | | | $ | 4,593 | | | $ | 2,671 | | | 58 | % |
| General and administrative | General and administrative | 2,833 | | | 1,191 | | | 1,642 | | | 138 | % | General and administrative | 3,507 | | | 1,177 | | | 2,330 | | | 198 | % |
| Total operating expenses | Total operating expenses | 7,777 | | | 6,232 | | | 1,545 | | | 25 | % | Total operating expenses | 10,771 | | | 5,770 | | | 5,001 | | | 87 | % |
| Loss from operations | Loss from operations | (7,777) | | | (6,232) | | | (1,545) | | | 25 | % | Loss from operations | (10,771) | | | (5,770) | | | (5,001) | | | 87 | % |
| Total other income (expense) | Total other income (expense) | 218 | | | (1,067) | | | 1,285 | | | (120) | % | Total other income (expense) | 113 | | | (1,428) | | | 1,541 | | | (108) | % |
| Net loss | Net loss | $ | (7,559) | | | $ | (7,299) | | | $ | (260) | | | Net loss | $ | (10,658) | | | $ | (7,198) | | | $ | (3,460) | | |
Research and Development Expenses
Research and development expenses were $4.9$7.3 million for the three months ended JuneSeptember 30, 2023, compared to $5.0$4.6 million for the three months ended JuneSeptember 30, 2022. The decreaseincrease of $0.1$2.7 million was primarily due to the GIRF grant offsetting increasedGMP manufacturing and clinical trial expenses as the Company focused onadvanced ELI-002 clinical development.
General and Administrative Expenses
General and administrative expenses were $2.8$3.5 million for the three months ended JuneSeptember 30, 2023, compared to $1.2 million for the three months ended JuneSeptember 30, 2022. The increase of $1.6$2.3 million was primarily due to higher personnel-related costs in support of organizational growth and higher professional fees incurred in connection with operating as a public company.
Other Income (Expense)
Other income (expense) for the three months ended September 30, 2023 was income of $0.1 million compared to expense of $1.4 million for the three months ended September 30, 2022. The decrease of $1.5 million was primarily due to reduced interest expense associated with the conversion of the convertible notes to preferred stock as part of the Series C Preferred Stock offering.
Comparison of the Nine Months Ended September 30, 2023 and 2022
The following table summarizes our results of operations for the periods indicated:
| | | | | | | | | | | | | | | | | | | | | | | |
| Nine Months Ended
September 30, | | | | |
| 2023 | | 2022 | | $ Change | | % Change |
| | | | | | | |
| (In thousands, except percentages) |
| Operating expenses: | | | | | | | |
| | | | | | | |
| Research and development | $ | 17,692 | | | $ | 13,813 | | | $ | 3,879 | | | 28 | % |
| General and administrative | 8,661 | | | 3,959 | | | 4,702 | | | 119 | % |
| | | | | | | |
| Total operating expenses | 26,353 | | | 17,772 | | | 8,581 | | | 48 | % |
| Loss from operations | (26,353) | | | (17,772) | | | (8,581) | | | 48 | % |
| Other income (expense), net | 107 | | | (3,785) | | | 3,892 | | | (103) | % |
| Net loss | $ | (26,246) | | | $ | (21,557) | | | $ | (4,689) | | | |
Research and Development Expenses
Research and development expenses were $17.7 million for the nine months ended September 30, 2023, compared to $13.8 million for the nine months ended September 30, 2022. The increase of $3.9 million was primarily due to an increase in external costs associated with ELI-002 manufacturing and clinical trials.
General and Administrative Expenses
General and administrative expenses were $8.7 million for the nine months ended September 30, 2023, compared to $4.0 million for the nine months ended September 30, 2022. The increase of $4.7 million was primarily due to higher personnel-related costs in support of organizational growth and higher professional fees incurred in connection with the Merger and operating as a public company.
Other Income/Income (Expense)
Other income/(expense)expense for the threenine months ended JuneSeptember 30, 2023 was income of $0.2$0.1 million compared to expense of $1.1$3.8 million for the threenine months ended JuneSeptember 30, 2022. The decrease of $1.3 million was primarily due to reduced interest expense associated with the conversion of the convertible notes to preferred stock as part of the Series C Preferred Stock offering.
Comparison of the Six Months Ended June 30, 2023 and 2022
The following table summarizes our results of operations for the periods indicated:
| | | | | | | | | | | | | | | | | | | | | | | |
| Six Months Ended
June 30, | | | | |
| 2023 | | 2022 | | $ Change | | % Change |
| | | | | | | |
| (In thousands, except percentages) |
| Operating expenses: | | | | | | | |
| | | | | | | |
| Research and development | $ | 10,428 | | | $ | 9,220 | | | $ | 1,208 | | | 13 | % |
| General and administrative | 5,154 | | | 2,782 | | | 2,372 | | | 85 | % |
| | | | | | | |
| Total operating expenses | 15,582 | | | 12,002 | | | 3,580 | | | 30 | % |
| Loss from operations | (15,582) | | | (12,002) | | | (3,580) | | | 30 | % |
| Other income (expense), net | (4) | | | (2,357) | | | 2,353 | | | (100) | % |
| Net loss | $ | (15,586) | | | $ | (14,359) | | | $ | (1,227) | | | |
Research and Development Expenses
Research and development expenses were $10.4 million for the six months ended June 30, 2023, compared to $9.2 million for the six months ended June 30, 2022. The increase of $1.2 million was primarily due to an increase in external costs associated with manufacturing and clinical trials.
General and Administrative Expenses
General and administrative expenses were $5.2 million for the six months ended June 30, 2023, compared to $2.8 million for the six months ended June 30, 2022. The increase of $2.4 million was primarily due to higher personnel-related costs in support of organizational growth and higher professional fees incurred in connection with the Merger and operating as a public company.
Other Income/(Expense)
Other expense for the six months ended June 30, 2023 was income of $0.0 million compared to expense of $2.4 million for the six months ended June 30, 2022. The decrease of $2.4$3.9 million was primarily due to reduced interest expense associated with the convertible notes.
Liquidity and Capital Resources
Sources and Uses of Liquidity
Our operations through JuneSeptember 30, 2023 have been financed primarily by aggregate net proceeds of $89.1$99.6 million from the issuance of common stock, convertible preferred stock, convertible notes, and the exercise of stock options and common stock warrants.warrants and proceeds from the Merger. Since inception, we have had significant operating losses. Our net loss was $15.6$26.2 million and $14.4$21.6 million for the sixnine months ended JuneSeptember 30, 2023 and sixnine months ended JuneSeptember 30, 2022, respectively. As of JuneSeptember 30, 2023, we had an accumulated deficit of $122.6$133.3 million and $21.7$14.8 million in cash and cash equivalents. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses.
Our losses from operations, negative operating cash flows and accumulated deficit, as well as the additional capital needed to fund operations for at least twelve months following the issuance of the unaudited condensed consolidated financial statements, raise substantial doubt about our ability to continue as a going concern. We expect to incur substantial expenditures in the foreseeable future for the development of our product candidates and will require additional financing to continue this development. The unaudited condensed consolidated financial statements appearing elsewhere in this Form 10-Q have been prepared on a basis that assumes that we will continue as a going concern, which contemplates the realization of assets and satisfaction of liabilities in the normal
course of business. The unaudited condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should we be unable to continue as a going concern. We plan to address this condition through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources, including licensing arrangements, partnerships and collaborations with other companies or other strategic transactions. However, there is no assurance that we will be successful in raising additional capital or that such additional funds will be available on acceptable terms, if at all. Should we be unable to raise this amount of capital our operating plans will be limited to the amount of capital that we can access. We may also consider steps to reduce our operating expenses. There can be no assurances that we will be successful in any of the foregoing.
Future Cash Needs and Funding Requirements
Based on our current operating plan, we believe our cash and cash equivalents will be sufficient to fund our planned operations throughinto the first quarter of calendar year 2023.2024. However, we have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all our available capital resources sooner than we expect. We are unable to estimate the exact amount of our operating capital requirements. The amount and timing of our future funding requirements will depend on many factors, including, but not limited to:
▪the scope, progress, results and costs of researching and developing product candidates, and conducting preclinical studies and clinical trials;
▪the outcome of any future clinical trials, for any existing or future product candidates;
▪whether we are able to take advantage of any FDA expedited development and approval programs for any of its product candidates;
▪the outcome, costs and timing of seeking and obtaining and maintaining FDA and any foreign regulatory approvals;
▪the costs associated with any delays we may encounter as a result of evolving regulatory requirements or adverse results with respect to any of our product candidates;
▪the number and characteristics of product candidates we pursue, including product candidates in preclinical development;
▪the ability of our product candidates to progress through clinical development successfully;
▪our need to expand our research and development activities, including to conduct additional clinical trials;
▪market acceptance of our product candidates, including physician adoption, market access, pricing and reimbursement;
▪the costs of acquiring, licensing or investing in businesses, products, product candidates and technologies;
▪our ability to maintain, expand and defend the scope of our intellectual property portfolio, including the amount and timing of any payments potentially required to make, or that we may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;
▪our need and ability to hire additional personnel, including management, clinical development, medical and commercial personnel;
▪the effect of competing technological, market developments and government policy;
▪the costs associated with being a public company, including our need to implement additional internal systems and infrastructure, including financial and reporting systems;
▪the costs associated with securing and establishing commercialization and manufacturing capabilities, as well as those associated with packaging, warehousing and distribution;
▪the economic and other terms, timing of and success of our existing licensing arrangements and any collaboration, licensing or other arrangements into which we may enter in the future and timing and amount of payments thereunder; and
▪the timing, receipt and amount of sales and general commercial success of any future approved products, if any.
Until such time as we can generate significant revenue from sales of product candidates, if ever, we expect to finance our operations through the sale of common stock in public offerings and/or private equity offerings orplacements, debt financings, or through other capital sources, of capital, including licensing arrangements, partnerships and collaborations licenses, creditwith other companies or loan facilities, receipt of research contributions or grants, tax credit revenue or a combination of one or more of these funding sources.other strategic transactions. Adequate funding may not be available to us on acceptable terms, or at all. To the extent we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raisesraise funds through additional collaborations, or other similar arrangements with third parties, we may have to
relinquish valuable rights to itsour technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to and/or may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates itself.
Summary Statement of Cash Flows
The following table sets forth a summary of our net cash flow activity for the sixnine months ended JuneSeptember 30, 2023 and 2022 (in thousands):
| | | Six Months Ended
June 30, | | Nine Months Ended
September 30, |
| | 2023 | | 2022 | | 2023 | | 2022 |
| Net cash provided by (used in) | Net cash provided by (used in) | | | | Net cash provided by (used in) | | | |
| Operating activities | Operating activities | $ | (17,614) | | | $ | (9,517) | | Operating activities | $ | (22,798) | | | $ | (14,903) | |
| Investing activities | Investing activities | 13 | | | (559) | | Investing activities | (32) | | | (559) | |
| Financing activities | Financing activities | 31,552 | | | 1,247 | | Financing activities | 31,611 | | | 10,026 | |
| Effect of foreign currency on cash | Effect of foreign currency on cash | (2) | | | — | | Effect of foreign currency on cash | — | | | — | |
| Net increase (decrease) in cash | Net increase (decrease) in cash | $ | 13,949 | | | $ | (8,829) | | Net increase (decrease) in cash | $ | 8,781 | | | $ | (5,436) | |
Operating Activities
For the sixnine months ended JuneSeptember 30, 2023, net cash used in operating activities was $17.6$22.8 million, which primarily consisted of a net loss of $15.6$26.2 million and the use of cash fromwhich was partially offset by the change in net operating assets and liabilities of $3.2$1.6 million which was partially offset byand the net non-cash charges of $1.2$1.8 million. The use of cash due toprovided by the change in net operating assets and liabilities was due to a $1.4$0.2 million reductionincrease in deferred research obligation, $1.1a $2.0 million increase in prepaid expenses, $0.3 million decrease in accrued expense and accounts payable, and $0.3$0.6 million decrease in operating lease. The net non-cash charges were primarily related to $1.1 million of interest expense related to the accretion of promissory notes payable, $0.5$0.8 million of stock-based compensation, $0.4$0.6 million decrease in the right of use asset, $0.2$0.3 million of depreciation offset by $0.4 million increase in the fair value of the embedded derivative associated with the promissory notes payable and $0.6 million of gain on the settlementextinguishment of the promissory notes payable.
For the sixnine months ended JuneSeptember 30, 2022, net cash used in operating activities was $9.5$14.9 million, which primarily consisted of a net loss of $14.4 million partially offset by net non-cash charges of $3.1$21.6 million and $1.7 millionthe use of cash from the change in net operating assets and liabilities.liabilities of $1.7 million which was partially offset by net non-cash charges of $5.0 million. The gain in cash dueprovided by to the change in net operating assets and liabilities was due to a $1.9$2.1 million increase in deferred research obligation, a $1.3 million increase in accounts payable and accrued expenses, a $0.1$1.4 million decrease in prepaid expenses and a $0.2$0.4 million decrease in operating lease. The net non-cash charges were primarily related to $2.4$3.5 million of interest expense related to convertible notes, $0.3$0.4 million of stock-based compensation, and $0.2$0.3 million of depreciation, off set by $0.1$0.5 million decrease in the right of use asset, and a $0.3 million decrease in the fair value of the embedded derivative associated with the convertible notes.
Investing Activities
For the sixnine months ended JuneSeptember 30, 2023, cash provided by or used in investing activities was immaterial.
For the sixnine months ended JuneSeptember 30, 2022, net cash used in investing activity was $0.6 million, which was driven by the purchase of fixed assets.property and equipment.
Financing Activities
For the sixnine months ended JuneSeptember 30, 2023, net cash provided by financing activities was $31.6 million as a result of the Merger.
For the sixnine months ended JuneSeptember 30, 2022, net cash provided by financing activities was $1.2$10.0 million, consisting primarily of proceeds from the issuance of preferred stock.
Critical Accounting Policies and Significant Judgements and Estimates
Our condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles in the United States (“U.S. GAAP”). The preparation of our condensed consolidated financial statements and related disclosures requires us to make estimates and judgments affecting the reported amounts of assets, liabilities, costs and expenses. We base our estimates on historical experience, known trends and events and various other factors we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies are described under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Use of Estimates” in our Current Report on Form 8-K filed with the SEC on June 2, 2023. During the sixnine months ended JuneSeptember 30, 2023, except as described in Note 2 to the unaudited interim condensed consolidated financial statements appearing elsewhere in this Quarterly Report on Form 10-Q, there were no material changes to our critical accounting policies from those previously disclosed.
Emerging Growth Company and Smaller Reporting Company Status
We are a smaller reporting company and an emerging growth company, as defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay the adoption of new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years of audited financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor's report on internal controls over financial reporting pursuant to Sarbanes-Oxley Act of 2002, as amended (“Sarbanes-Oxley”) an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less extensive disclosure about our executive compensation arrangements.
We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that (i) we are no longer an emerging growth company or (ii) we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our condensed consolidated financial statements may not be comparable to companies that comply with new or revised accounting standards as of public company effective dates.
We will remain an emerging growth company until the earliest of (i) December 31, 2026, (ii) the last day of our first fiscal year in which we have total annual gross revenue of $1.235 billion or more, (iii) the date on which we are deemed to be a “large accelerated filer,” as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which means the market value of equity securities held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period.
Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company” and/or “non-accelerated filer” which may allow us to take advantage of many of the same exemptions
from disclosure requirements including not being required to comply for a period of time with the auditor attestation requirements of Section 404 of Sarbanes-Oxley, and reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information required under this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
TableOur management, with the participation of Contents
our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures at September 30, 2023. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to its management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer, after evaluating the effectiveness of our “disclosure controls and procedures” (as defined in the Exchange Act Rule 13a-15(e), or Rule 15d-15(e)), with the participation of our management, have each concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were not effective due to the material weakness in internal control over financial reporting described below.
During the 2022 audit procedures performed around convertible preferred stock, an adjustment in the amount of $843,000, related to the modification of the Series A preferred stock dividend rights, and associated issuance of warrants during 2018 was identified. It was further determined the modification of the dividend rights and the issuance of warrants should have been accounted for as an extinguishment.
A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be detected on a timely basis. Although the identified adjustment was immaterial to our financial statements, we determined that there was a risk that a similar event could have occurred without being prevented or detected on a timely basis that could have given rise to a potentially material misstatement in our financial statements or disclosures.
Although we have initiated efforts to remediate this material weakness, including enhanced review processes to address infrequent, complex transactions, the material weakness has not been fully remediated as of JuneSeptember 30, 2023 and continues to be disclosed as a material weakness in the Company’s Form 10-Q for the three and sixnine month periods ended JuneSeptember 30, 2023.
Our remediation efforts are intended to address the identified material weakness. Management is committed to continuous improvement of our internal control over financial reporting and will continue to diligently review our internal control over financial reporting.
Changes in Internal Control Over Financial Reporting
Other than the material weakness described above, there were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)) under the Exchange Act) that occurred during the
quarter ended JuneSeptember 30, 2023, that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Inherent Limitation on the Effectiveness Over Financial Reporting
The effectiveness of any system of internal control over financial reporting, including ours, is subject to inherent limitations, including the exercise of judgment in designing, implementing, operating, and evaluating the controls and procedures, and the inability to eliminate misconduct completely. Accordingly, any system of internal control over financial reporting, including ours, no matter how well designed and operated, can only provide reasonable and not absolute assurances. In addition, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business, but there can be no assurance such improvements will be sufficient to provide us with effective internal control over financial reporting.
Part II OTHER INFORMATION
Item 1. Legal Proceedings
From time to time, we may be involved in legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of business or otherwise. Following announcement of the merger agreement with Elicio on January 17, 2023, and the filing of a Registration Statement on Form S-4 on February 13, 2023, a lawsuit was filed in the United States District Court for the Eastern District of New York on February 17, 2023 by a purported stockholder of Angion in connection with the proposed merger between Angion and Elicio. The lawsuit was captioned Klein v. Angion Biomedica Corp., et al., No. 1:23-cv-01313 (E.D.N.Y.). The Klein complaint named as defendants Angion, and the members of the Angion Board. The Klein complaint alleged claims for violations of Section 14(a) of the Exchange Act and Rule 14a-9 promulgated thereunder against all defendants, and violations of Section 20(a) of the Exchange Act against the members of the Angion Board. The plaintiff contended that the registration statement on Form S-4 initially filed with the SEC on February 13, 2023 omitted or misrepresented material information regarding the proposed merger between Angion and Elicio, rendering the registration statement false and misleading. The Klein complaint sought injunctive and declaratory relief, as well as damages. On February 21, 2023, the plaintiff filed a notice of voluntary dismissal of the Klein lawsuit. Although the plaintiffs voluntarily dismissed this case, litigation of this type is prevalent in mergers involving public companies, and other potential plaintiffs may file lawsuits challenging the Merger.
The outcome of any additional future litigation is uncertain. Such litigation, if not resolved, could result in substantial costs to us, including any costs associated with the indemnification of directors and officers.
Item 1A. Risk Factors
Investing in our common stock involves a high degree of risk. You should carefully consider the risk factors, described in our Form 8-K filed on June 2, 2023 as well as the other information in this Quarterly Report on Form 10-Q, before deciding whether to invest in shares of our common stock. There have been no material changes in our risk factors from those described in our current report on Form 8-K filed on June 2, 2023, other than the updates to the risk factors set forth below.
We may be unsuccessful in raising the capital necessary to address our going concern issues, or if we are successful, it may be on terms that are highly dilutive to existing stockholders.
Historically, we funded our operations by raising capital from external sources and from the Merger. However, we are currently facing significant challenges to our ability to raise capital through the sale of common stock, including the following factors:
•in general, it is difficult for development stage companies to raise capital under current market conditions, especially those with early-stage programs like ours;
•the perception that we may be unable to continue as a going concern may impede our ability to attract further equity investment; and
•our common stock has limited trading volume, which limits the demand for our common stock.
Given these factors, there can be no assurances we will be successful at raising sufficient capital to address our going concern issues. However, if we are successful, it may be on terms that are very highly dilutive to existing stockholders.In addition, if we are unable to raise additional capital, we will have to delay, curtail or eliminate one or more of our research and development programs or cease operations.
We have identified a material weakness in our internal control over financial reporting related to our control environment. If we do not remediate the material weaknesses in our internal control over financial reporting, or if we fail to establish and maintain effective internal control, we may not be able to accurately report our financial results, which may cause investors to lose confidence in our reported financial information and may lead to a decline in the market price of our stock.
As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls. Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting in our periodic reports filed with the SEC. However, while we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. If we identify one or moreadditional material weaknesses, it could result in an adverse reaction in the financial markets due to a loss of confidence in the reliability of our financial statements. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented, or detected and corrected on a timely basis.
We have identified a material weakness in our internal control over financial reporting related to our control environment. More specifically, we have determined that we have not maintained adequate formal accounting policies, processes and controls related to complex transactions as a result of a lack of finance and accounting staff with the appropriate GAAP technical expertise needed to identify, evaluate and account for complex and non-routine transactions.
Over the next several months, we plan to implement a number of measures to address the material weakness we have identified. We plan to design additional controls around identification, documentation and application of
technical accounting guidance with particular emphasis on complex and non-routine transactions. These controls are expected to include an additional review process to ensure that the correct conclusions are reached with respect to complex and non-routine transactions and avoid the potential for a material misstatement of our financial statements. We intend to complete the implementation of our remediation plan during 2023. However, we cannot assure you that we will be successful in remediating the material weakness we identified or that our internal control over financial reporting, as modified, will enable us to identify or avoid material weaknesses in the future.
Any failure to remediate the material weakness we identified or develop or maintain effective controls, or any difficulties encountered in their implementation or improvement, could harm our operating results or cause us to fail to meet our reporting obligations and may result in a restatement of our financial statements for prior periods. Any failure to remediate the material weakness we identified or implement and maintain effective internal control over financial reporting could also adversely affect the results of management reports and independent registered public accounting firm audits of our internal control over financial reporting that we will eventually be required to include in our periodic reports that will be filed with the SEC. Ineffective disclosure controls and procedures, and internal control over financial reporting could also cause investors to lose confidence in our reported financial and other information, which would likely have a negative effect on the market price of our common stock.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Recent Sales of Unregistered Securities
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
During the fiscal quarter ended JuneSeptember 30, 2023, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement.”
Item 6. Exhibits
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Exhibit
Number | | Exhibit
Description | | Incorporated by Reference | | Filed Herewith | |
| | Form | | Date | | Number | | |
| 2.1 | | | | 8-K | | 1/17/2023 | | 2.1 | | | |
| 3.1 | | | | 8-K | | 2/09/2021 | | 3.1 | | | |
| 3.2 | | | | 8-K | | 2/09/2021 | | 3.2 | | | |
| 3.43 | | | | 8-K | | 6/02/2023 | | 3.3 | | | |
| 3.4 | | | | 8-K | | 6/02/2023 | | 3.4 | | | |
| 3.5 | | | | 8-K | | 6/02/2023 | | 3.5 | | | |
| 4.1 | | Reference is made to exhibits 3.1 through 3.2. | | | | | | | | | |
| 4.2 | | | | S-1/A | | 2/01/2021 | | 4.2 | | | |
| 4.3 | | | | S-1 | | 1/15/2021 | | 4.3 | | | |
| 4.4 | | | | S-1 | | 1/15/2021 | | 4.6 | | | |
| 10.1+ | | | | 8-K | | 6/02/2023 | | 10.2 | | | |
| 10.2 | | | Form of Indemnification Agreement between Elicio Therapeutics, Inc. and each of its directors and officers. | 8-K | | 6/02/2023 | | 10.8 | | | |
| 10.3 | | | | 8-K | | 6/02/2023 | | 10.13 | | | |
| 10.4 | | | | S-4/A | | 3/29/2023 | | 10.29 | | | |
| 10.5 | | | | S-4/A | | 3/29/2023 | | 10.30 | | | |
| 10.6 | | | | S-4/A | | 3/29/2023 | | 10.31 | | | |
| 10.7 | | | | S-4/A | | 3/29/2023 | | 10.32 | | | |
| 10.8 | | | | S-4/A | | 3/29/2023 | | 10.27 | | | |
| 10.9 | | | | S-4/A | | 3/29/2023 | | 10.28 | | | |
| 10.10 | | | | S-4/A | | 3/29/2023 | | 10.25 | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Exhibit
Number | | Exhibit
Description | | Incorporated by Reference | | Filed Herewith | |
| | Form | | Date | | Number | | |
| 10.11 | | | | S-4/A | | 3/29/2023 | | 10.26 | | | |
| 10.12 | | | Note Purchase Agreement, dated Janaury 17, 2023, by and between Elicio Therapeutics and Angion Biomedica Corp., and Form of Promissory Note | 8-K | | 1/17/2023 | | 10.1 | | | |
| 10.13 | | | | S-4/A | | 3/29/2023 | | 10.34 | | | |
| 31.1 | | | | | | | | | | X | |
| 31.2 | | | | | | | | | | X | |
| 32.1^ | | | | | | | | | | X | |
| 32.2^ | | | | | | | | | | X | |
| 101.INS | | XBRL Instance Document. | | | | | | | | X | |
| 101.SCH | | XBRL Taxonomy Extension Schema Document. | | | | | | | | X | |
| 101.CAL | | XBRL Taxonomy Extension Calculation Linkbase Document. | | | | | | | | X | |
| 101.DEF | | XBRL Taxonomy Extension Definition Linkbase Document. | | | | | | | | X | |
| 101.LAB | | XBRL Taxonomy Extension Label Linkbase Document. | | | | | | | | X | |
| 101.PRE | | XBRL Taxonomy Extension Presentation Linkbase Document. | | | | | | | | X | |
| 104 | | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). | | | | | | | | X | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Exhibit
Number | | Exhibit
Description | | Incorporated by Reference | | Filed Herewith | |
| | Form | | Date | | Number | | |
| 10.1+ | | | | 8-k | | 10/20/2023 | | 10.1+ | | | |
| 10.2+ | | | | | | | | | | X | |
| 31.1 | | | | | | | | | | X | |
| 31.2 | | | | | | | | | | X | |
| 32.1^ | | | | | | | | | | X | |
| 32.2^ | | | | | | | | | | X | |
| 101.INS | | XBRL Instance Document. | | | | | | | | X | |
| 101.SCH | | XBRL Taxonomy Extension Schema Document. | | | | | | | | X | |
| 101.CAL | | XBRL Taxonomy Extension Calculation Linkbase Document. | | | | | | | | X | |
| 101.DEF | | XBRL Taxonomy Extension Definition Linkbase Document. | | | | | | | | X | |
| 101.LAB | | XBRL Taxonomy Extension Label Linkbase Document. | | | | | | | | X | |
| 101.PRE | | XBRL Taxonomy Extension Presentation Linkbase Document. | | | | | | | | X | |
| 104 | | Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101). | | | | | | | | X | |
†
Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.
+ Management contract or compensatory plan arrangement.
^ The certification that accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, is not deemed “filed” by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.
+ Indicated management contract or compensatory plan
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| | | | | | | | | | | | | | |
| | ELICIO THERAPEUTICS, INC. |
| | | | |
| | By: | | /s/ ROBERT CONNELLY |
| Date: | August 11,November 13, 2023 | | | Robert Connelly President and Chief Executive Officer (Principal Executive Officer) |
| | | | | | | | | | | | | | |
| | ELICIO THERAPEUTICS, INC. |
| | | | |
| | By: | | /s/ BRIAN PIEKOS |
| Date: | August 11,November 13, 2023 | | | Brian Piekos Chief Financial Officer (Principal Financial Officer and Principal Accounting Officer) |